The present disclosure relates to medicine injection and disease management systems, devices, and methods, particularly those related to the management of diabetes and/or the delivery of insulin. In some embodiments, systems, methods, and devices provided herein can personalize user-selectable meal sizes for a user to enter meal data for purposes of obtaining recommendations regarding one or more medication doses. In some cases, one or more buttons (e.g., user-selectable icons, physical press buttons, etc.) can be personalized to describe an amount or range of amounts of insulin to be delivered and/or carbohydrates to be consumed.
Diabetes mellitus is a chronic metabolic disorder caused by an inability of a person's pancreas to produce sufficient amounts of the hormone, insulin, such that the person's metabolism is unable to provide for the proper absorption of sugar and starch. This failure leads to hyperglycemia, i.e., the presence of an excessive amount of analyte, such as glucose, within the blood plasma. Persistent hyperglycemia has been associated with a variety of serious symptoms and life threatening long-term complications such as dehydration, ketoacidosis, diabetic coma, cardiovascular diseases, chronic renal failure, retinal damage and nerve damages with the risk of amputation of extremities. Self-monitoring of blood glucose and the self-administration of insulin is the typical method for treating diabetes. The “correct” insulin dosage is a function of the level of glucose in the blood. Insufficient insulin dosages can result in hyperglycemia, and excessive insulin dosages can result in hypoglycemia, which can result in clumsiness, trouble talking, confusion, loss of consciousness, seizures, or death. Accordingly, people with diabetes (PWDs) face a considerable cognitive burden in determining an appropriate dosage of insulin.
In order to assist with this self-treatment, many diabetes-related devices (e.g., blood glucose meters, insulin pumps, etc.) are equipped with insulin bolus calculators that have the user input a number of carbohydrates consumed (or about to be consumed) and the bolus calculator outputs a recommended size for the insulin bolus dosage. Although bolus calculators remove some of the calculations that need to be made by the user in determining an appropriate insulin bolus dosage, bolus calculators still burden the user with the mental task of determining the number of carbohydrates in their meal and often require manual entry of data. Accordingly, there is a need for methods, systems, and devices that further reduce the cognitive burden on the user while improving the accuracy of a recommended insulin bolus dosage.
Systems, devices and methods provided herein can be equipped to simplify calculation of a recommended insulin dosage by simplifying a meal announcement process and/or simplifying the collection of an estimated glucose value (EGV). A meal announcement process can be simplified by providing a user interface that includes one or more meal announcement buttons, which can be user-selectable icons on a touchscreen, physical press buttons, jog dials, voice activation commands, etc. In some cases, meal announcement buttons can be located on part of an insulin delivery device or on an accessory for an insulin delivery device. In some cases, the insulin delivery device can be an insulin pen and a dose capture pen cap including the meal announcement buttons. In some cases, an insulin delivery device or an accessory therefor can be in wireless communication with a remote user interface device (e.g., a mobile application on a smartphone) and the meal announcement buttons can be on the remote user interface device (either as physical press buttons or as user-selectable icons on a touch screen). The one or more meal announcement buttons can be personalized based on user's use of the system. Such personalization may be based on a user interacting with various buttons or features (e.g., the user selecting various meal sizes for boluses), by providing boluses and measuring the effect for the boluses over time, or any other use of devices or systems in accordance with the present disclosure.
One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.
In accordance with one or more devices, systems, or methods of the present disclosure, a device or system may include a blood glucose monitor or sensor.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a flash glucose monitor that includes a flash near field communication circuit, and a system near field communication circuit in communication with the processor. In these and other embodiments, the processor may be adapted to receive the blood glucose data via near field communications (NFC) when the system near field communication circuit and the flash near field communication circuit are brought within an NFC communication distance.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a continuous glucose monitor, and the processor may be adapted to receive wireless communications from the continuous glucose monitor at predetermined time intervals.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a continuous glucose monitor, and the processor may be adapted to receive wireless communications from the continuous glucose monitor at predetermined time intervals.
In accordance with one or more devices, systems, or methods of the present disclosure, the user-selectable icons or buttons may each initially represent an amount of carbohydrates in 5 gram or 10 gram increments.
In accordance with one or more devices, systems, or methods of the present disclosure, the amount of carbohydrates initially represented by each of the plurality of icons may be determined based on an insulin Sensitivity Factor (ISF), a Carb Ratio (CR), a body weight, an age, a total daily basal (TDB) rate, a daily dosage of Long-Acting Insulin, a weight averaged total daily dosage (TDD) of insulin and/or a combination thereof of a person with diabetes (PWD).
In accordance with one or more devices, systems, or methods of the present disclosure, the processor may be further configured to determine an insulin delivery amount based on an amount of carbohydrates associated with a selected one of the user-selectable icons or buttons and/or the blood glucose data.
In accordance with one or more devices, systems, or methods of the present disclosure, the user-selectable icons or buttons may each represent a number of units of insulin that are needed to compensate for each meal, rounded to the nearest 0.5 units.
In accordance with one or more devices, systems, or methods of the present disclosure, the updating of the meal characteristics associated with each of the plurality of user-selectable icons or buttons may be determined from postprandial blood glucose data after the user has selected a given user-selectable icon or button.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a flash glucose monitor that includes a flash near field communication circuit, and the systems or devices may further include one or more system near field communication circuits in communication with the processor. In these and other cases, the processor may be adapted to receive the postprandial blood glucose data via near field communications (NFC) when the one or more system near field communication circuits and the flash near field communication circuit are brought within an NFC communication distance. Additionally, the processor may be adapted to send a prompt to the user to retrieve the postprandial blood glucose data by bringing one of the one or more system near field communication circuits into close proximity to the flash glucose monitor at a predetermined time after insulin is delivered or one of the user-selectable icons or buttons has been selected by the user.
In accordance with one or more devices, systems, or methods of the present disclosure, the user interface may be adapted to display a bolus recommendation based on the blood glucose data and a selection of one of the user-selectable icons or buttons.
In accordance with one or more devices, systems, or methods of the present disclosure, the processor may determine the bolus recommendation based on factors selected from the number of carbohydrates divided by the PWD's carbohydrate-to-insulin ratio, a difference between the current blood glucose level and a target blood glucose level divided by the PWD's insulin sensitivity factor, a reading from a blood glucose meter (BGM), data from a continuous glucose monitor (CGM), blood glucose trend data, Insulin on Board (IOB) data, Carbohydrates on Board (COB) data, whether the PWD is or plans to exercise, whether the PWD is sick, whether the PWD is pregnant, whether the PWD is experiencing menses, and whether the PWD has consumed certain medications.
In accordance with one or more devices, systems, or methods of the present disclosure, the processor may be further adapted to receive dosage data from the insulin delivery device, and the update the meal characteristics associated with each of the user-selectable icons or buttons may be based upon postprandial blood glucose data after the user has selected that user-selectable icon or button, the dosage data, or a combination thereof.
In accordance with one or more devices, systems, or methods of the present disclosure, the insulin delivery device may include an insulin pen, and the user interface may be part of the insulin pen, part of a pen accessory adapted to reversibly connect to an insulin pen, or part of a mobile application for a smartphone in wireless communication with an insulin pen or an accessory therefore. In these and other embodiments, the devices or systems may be adapted to detect amounts of insulin remaining in or delivered by one or more insulin pens.
In accordance with one or more devices, systems, or methods of the present disclosure, the pen accessory may be adapted to reversibly connect to an insulin pen, where the pen accessory may include a pen cap that is adapted to detect amounts of insulin remaining in an insulin pen during placement or removal from the insulin pen or when secured to the insulin pen.
In accordance with one or more devices, systems, or methods of the present disclosure, the user interface may be located on the mobile application for a smartphone, where the smartphone further includes the processor, and the insulin pen or an accessory therefor is adapted to detect insulin amount or delivery data and wirelessly communicate the insulin amount or delivery data to the processor.
One or more embodiments of the present disclosure may include a cap for an insulin pen that includes one or more sensors adapted to detect the position of a plunger within an insulin pen, and a user interface that includes one or more user-selectable icons or buttons adapted to announce a meal or an intent to have a meal.
In accordance with one or more devices, systems, or methods of the present disclosure, the cap may include a processor and memory, where the processor may be adapted to determine a time and dosage for an insulin delivery based on data from the one or more sensors and store that information in the memory.
In accordance with one or more devices, systems, or methods of the present disclosure, the user interface may include at least 2, and no more than 6, user-selectable icons or buttons adapted to announce a meal or an intent to have a meal, each representing different meal characteristics stored for each button in the memory.
In accordance with one or more devices, systems, or methods of the present disclosure, the user interface may include a display adapted to display a recommended dosage based at least in part on a selection of the one or more user-selectable icons.
In accordance with one or more devices, systems, or methods of the present disclosure, the cap may include a wireless communication device adapted to communicate with a blood glucose monitor or sensor, where the display may be adapted to display a current blood glucose level, an indication of a current rate of change, a recommended correction bolus dosage based on glucose data, or a combination thereof.
In accordance with one or more devices, systems, or methods of the present disclosure, a wireless communication device of a cap may include an NFC circuit.
In accordance with one or more devices, systems, or methods of the present disclosure, the devices or systems may include an annunciator adapted to prompt the user to obtain blood glucose data from the blood glucose monitor or sensor at a predetermined time after the selection of the one or more user-selectable icons or buttons.
In accordance with one or more devices, systems, or methods of the present disclosure, the devices or systems may include an annunciator adapted to provide an alarm when data from a blood glucose monitor or sensor indicates a need to provide therapy.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a processor and memory, the memory storing meal characterizations for each of the one or more user-selectable icons or buttons, and the processor being adapted to receive blood glucose data and update the meal characterizations for each of the one or more user-selectable icons or buttons based on the blood glucose data.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include memory that can store multiple meal characterizations for a single user-selectable icon or button based on the time of day.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a cap that further includes a sensor adapted to detect a characterization of an insulin pen or a type of insulin in an insulin pen, a memory to store information about different types of insulin pens or different types of insulin, and a processor to determine the type of insulin pen or the type of insulin.
In accordance with one or more devices, systems, or methods of the present disclosure, the systems or devices may include a processor adapted to change the user interface dependent on the type of insulin pen or the type of insulin, where some types of insulin or insulin pens result in a user-interface that does not include any user-selectable icons or buttons adapted to announce a meal or an intent to have a meal.
Insulin delivery systems and devices, and methods for delivering insulin, can be designed to minimize the cognitive and active burden for people with diabetes (PWDs), or their caregivers, as they decide to administer insulin. In some embodiment's, methods, systems, and devices provided herein can passively capture diabetes-relevant data (e.g., insulin delivery data, blood glucose data, etc.) with or without providing the PWD (or a caregiver) with recommendations. In some embodiments, methods, systems, and devices provided herein can provide guidance regarding an appropriate dosage of insulin. In some embodiments, the dosage of insulin can be administered with an insulin delivery pen or syringe. In some cases, the insulin can be a long-acting insulin. In some cases, the insulin can be a quick-acting insulin. In some embodiments, an insulin delivery pen, or accessory therefor (e.g., a cap), can detect an amount of insulin delivered from the pen (or an amount of insulin that was set for delivery). In some cases, an insulin pen, or an accessory therefor, can include a user-interface, which can display data or recommendations to the user and/or permit the user to enter data into the insulin pen or accessory. The following exemplary system includes insulin delivery pens having dose capture pen caps, but alternative embodiments are also envisioned where the functionality disclosed herein is incorporated into other accessories for an insulin delivery pen or the insulin delivery pen itself.
Exemplary Insulin Delivery System
Glucose monitor or sensor 150 can be any suitable sensor device and/or monitoring system capable of providing data that can be used to estimate one or more blood glucose values. As shown, glucose monitor or sensor 150 can be a sensor configured to transmit blood glucose data wirelessly. For example, the glucose monitor or sensor 150 can include an optical communication device, an infrared communication device, a wireless communication device (such as an antenna), and/or chipset (such as a BLUETOOTH® device (e.g., BLUETOOTH® Low Energy, Classic BLUETOOTH®, etc.), a Near-field communication (NFC) device, an 802.6 device (e.g., Metropolitan Area Network (MAN), a ZIGBEE® device, etc.), a WiFi device, a WIMAX® device, cellular communication facilities, etc.), and/or the like. The glucose monitor or sensor 150 may exchange data with a network and/or any other devices or systems described in the present disclosure. In some cases, glucose monitor or sensor 150 can be interrogated with an NFC device by the user moving one or more components of the system near the glucose monitor or sensor 150 to power and/or transmit blood glucose data from the glucose monitor or sensor 150 to other components of system 100.
As shown, remote user interface device 110 is a smartphone, but any suitable remote user interface device can be used, such as a computer tablet, a smartphone, a wearable computing device, a smartwatch, a fitness tracker, a laptop computer, a desktop computer, a smart insulin pen (e.g., the dose capture caps 182 and/or 184), and/or other appropriate computing devices. As shown in the exemplary user interface of the exemplary mobile app running on the depicted smartphone, the user interface can include a bolus calculator button 114 and optionally other buttons for the user to enter data or to request recommendations. The exemplary user interface can also include a display of blood glucose data, past, present, or predicted. As shown, the user interface includes a graph of historical data from the previous 30 minutes 123, a continuation of that graph having projected data 124, a point indicator 122 showing the current (or most recent) estimated blood glucose value, and a display of the current (or most recent) estimated blood glucose value 121. The user interface can also include text explaining the glucose data 131, text providing suggested actions 132 and 133, such as text providing insulin, carbohydrates, or other therapy suggestions 132 and/or text suggesting that the user obtain blood glucose data 133. In some cases, the user interface can permit the user to click on the glucose data or otherwise navigate in the mobile app to obtain more detailed or more complete blood glucose data.
The user interface can also depict insulin data. In some cases, the user interface can indicate an amount of Insulin-on-Board (IOB) 135, which may be only for Quick-Acting Insulin. In some cases, an IOB calculation may be for both quick-acting and long-acting insulin. In some cases, the user interface can display the time and/or amounts of the most recent doses of quick-acting and/or long-acting insulins 134. In some cases, the user interface can permit the user to click on the insulin data or otherwise navigate in the mobile app to more detailed or more complete insulin delivery data. In some cases, a user interface can overlay blood glucose data and insulin delivery data in any suitable format, such as a graphical display of the timing of blood glucose data vs. the timing of insulin delivery data.
In use, a user (e.g., the PWD and/or a caregiver) can use system 100 to get recommendations regarding an appropriate insulin dosage. In the case of an upcoming need to deliver long-acting insulin, the message of 132 may change to provide a recommended long-acting insulin dosage. In some cases, a recommended dosage may appear on pen cap 184. In the case of the user wanting to deliver a bolus of quick-acting insulin, the user may press bolus calculator button 114 to enter into a bolus calculator. Although any suitable bolus calculator could be used in systems, methods, and devices provided herein,
Additionally, or alternatively, dose capture pen caps for the quick-acting insulin pen 160 can include a user interface that permits the user to announce a small meal, medium meal, or large meal.
Personalizing Meal Announcement Buttons
As discussed above, methods, devices, and systems provided herein can provide a user with meal announcement buttons that provide the user with a reduced number of meal size selection options, which can be based upon the user's normal meal size, which can thus reduce the cognitive burden on a user seeking to administer insulin for a meal while improving the accuracy of insulin bolus recommendations. This section describes ways that methods, systems, and devices provided herein can determine an amount of insulin and/or an amount of carbohydrates to associate with each of the meal selection buttons (e.g., 141-144, 221-223, 321-323). Optionally, additional buttons can be present, such as a button that indicates a tiny meal or an extra-large meal for the user, such that any number of buttons are within the scope of the present disclosure. Additionally or alternatively, the system may include a single button, icon, or mode for announcing a meal to systems or devices of the present disclosure.
In some cases, each of the meal announcement buttons 142-144, 221-223, 321-323 can be associated with a number of carbohydrates that is personalized for the user based on other user-specific dosage parameters entered by the user for an insulin delivery system (e.g., total daily long-acting insulin dosage (e.g., U/day), a total daily dose of insulin (e.g., total of long and quick acting), a carbohydrate-to-insulin ratio, an insulin sensitivity factor, a glucose setpoint, or a combination thereof). In some cases, the number of carbohydrates assigned to each preset icon or button can be personalized over time based on estimations of the size of each meal consumed when that icon or button is selected based on a glucose response after the consumption of each meal. In some cases, the number of carbohydrates assigned to each preset icon or button can be rounded to the nearest 5 grams of carbohydrates and displayed. In some cases, a number of carbohydrates for each button is not displayed. In some cases, a user may manually enter personalized meal sizes for a number of user-selectable icons or buttons. In some cases, a number of carbohydrates assigned to each user-selectable icon or button can be initially set at a predetermined starting point or can be determined based on entered user information, and then iteratively adjusted upward or downward based upon the glycemic response to that selected meal size and bolus over time.
Initial settings for one or more meal announcement buttons 142-144, 221-223, 321-323 included on a device or in a system provided herein can be preset with predetermined values or ranges (e.g., small=20 g or 15-25 g, medium=30 g or 30-45 g, and large=50 g or 50-75 g). Additionally or alternatively, the initial settings can be set based on entered user data or based on one or more user-specific dosage parameters entered into a device or system provided herein. In some cases, initial settings for the one or more user-selectable icons or buttons can be based on an initially entered or determined and programmed total daily long-acting insulin (TDLAI) dose (e.g., U/day). For example, the relationship between the LAI dose [U/day] and Geometric Mean Meal Size [g] as characterized by the line corresponding to the major axis of the hyperellipsoid is: μ*MS=12.1*BR0.387. The relationship between Geometric Mean Meal Size [g] and Geometric Standard Deviation Meal Size is: σ*MS=1.92−μ*MS/186 where MS may represent the meal size and BR may represent the basal rate of insulin. Accordingly, initial meal size groups may correspond to predetermined percentiles of the Meal Size distribution by combining the above equations, optionally rounding meal size groups to the nearest 1.5, or 10 grams. In some cases, the relationship between typical meal sizes and other user-specific dosage parameters can be determined according to population statistics. In some cases, the number of carbohydrates associated with each user-selectable icon or button can be displayed on and/or adjacent to the user-selectable icon or button, which can help a user understand how to use the insulin delivery device or system to avoid deskilling the user. For example, seeing the number of carbohydrates assumed for each meal size helps a user that thinks about meals in terms of carbohydrates to adjust to using buttons to indicate a size of a meal. Additionally, by starting with display numbers rounded to the nearest 5 grams, the user can perceive that precision is not required, thus also reducing the cognitive burden on the user. Additionally, as the system iterates to personalize the amount of carbohydrates for each particular user-selectable icon or button, the system can adjust these numbers by smaller units (e.g., by 1 gram) to demonstrate to the user that the system is adjusting the number of carbohydrates associated with user-selectable icon or button.
In some cases, the user interface may be configured such that a PWD may interact with the user interface to enter more detailed information regarding the bolus size outside of the default options. For example, a PWD may be presented with a series of pre-set sizes that are readily adjustable in increments of 5 g by selecting a size and scrolling up or down. By interacting further with the user device (e.g., pressing and holding on the meal size), the user may have the option to manually input a bolus size or adjust the size in increments of 1 g.
Methods, systems, and devices provided herein can update the number of carbohydrates associated with each user-selectable icon or button using any suitable method. In some cases, methods, systems, and devices can use postprandial blood glucose data (e.g., between 1 hour and 3 hours after an announced meal) to evaluate whether the PWD likely consumed significantly more or significantly less carbohydrates than programmed for the user-selectable icon or button. In some cases, one or more postprandial blood glucose thresholds can be used to evaluate the match between the amount of carbohydrates consumed and the amount of carbohydrates associated with a selected user-selectable meal icon or button. For example, methods, devices, and systems provided herein can ask a user for a postprandial blood glucose reading from a glucose sensor, glucose monitor, or blood glucose meter. In some cases, a glucose sensor can be a flash glucose monitor and methods, systems, and devices provided herein can prompt the user to interrogate the flash glucose monitor at a predetermined postprandial time period. As used herein, the term “flash glucose monitor” may refer to a device configured to provide blood glucose readings in response to a manual invocation of the device, typically by a physical signal (e.g., a button, tap, etc.) or a wireless signal (e.g., a near-field communication (NFC), BLUETOOTH® communication, etc.). Such blood glucose readings may be performed periodically and reported when the device is invoked, or may be taken when invoked. In some cases, methods, devices, and systems provided here can receive postprandial blood glucose data from a continuous glucose monitor. In some cases, methods, systems, and devices provided herein can use a single postprandial blood glucose data point and compare that to one or more upper thresholds and one or more lower thresholds for that period of time to determine whether the number of carbohydrates associated with that user-selectable meal icon or button should be adjusted upward or downward. For example, if a user selects a typical meal icon indicating a meal of 30 grams of carbohydrates, but the 2-hour postprandial blood glucose reading is above 200 mg/dL, the number of grams associated with that icon or button might be adjusted upward by 2 grams, if it is above 170 mg/dL, it might be adjusted upward by 1 gram, if it is below 130 mg/dL, it might be reduced by 1 gram, and if it is below 100 mg/dL, it might be reduced by 2 grams. Accordingly, over time the meal icons would be adjusted to more closely resemble the user's typical consumption patterns in a way that matches the user's mental model surrounding the meals that they eat. The particular thresholds can be determined based on the postprandial time, the number of grams associated with the meal icon or button, the CR, ISF, and daily dose of LAI, and setpoint of the PWD, etc.
In some cases, meal announcement buttons can be personalized based on the time of the day. For example, in some cases, a user may have a larger average dinner and smaller average morning meals, and methods, devices, and systems provided herein can estimate an amount of carbohydrates for a user based on the time of day. In some cases, the amount of carbohydrates and the meal sizes (S, M, L) can be displayed together to help a user understand that the personalization is specific to the user's daily pattern. In some cases, buttons can be personalized based on the day of the week (e.g., a user's weekend meal patterns might be significantly different than during weekdays).
Because diabetes is a highly personal disease that presents the PWD or their caregiver(s) with significant cognitive burdens surrounding the determination of appropriate dosages of insulin, some PWDs or caregivers develop their own techniques (or mental model) for estimating an appropriate dosage of insulin. Although methods, systems, and devices provided herein can be adapted to provide recommendations to a user, the user may be free to dose insulin according to the user's preferences and the user's specific knowledge of what the PWD is about to eat and/or is experiencing (e.g., exercise, sickness, etc.). In some cases, meal announcement buttons can change based on repeated patterns of a user administering doses of insulin above or below a recommended dosage of insulin so that the meal announcement buttons begin to match the user's mental model regarding a typical meal size. Adjustments to an amount of carbohydrates represented by each meal announcement button based on the actual dosage, however, may be determined based on the postprandial blood glucose readings of a PWD. For example, if the postprandial blood glucose readings indicate an appropriate dosage, it can indicate that the user's mental model is appropriate for that meal, and that the system can thus adjust the meal announcement buttons to match the user's mental model (e.g., reduce the size of the meal assumed for a (S) meal based on a repeated pattern of the user administering less insulin than recommended for an (S) meal selection if postprandial blood glucose readings are usually within a predetermined range). However, in some cases, methods, devices, and systems, provided herein can use postprandial blood glucose readings to determine if the user's mental model failed to determine the appropriate dose. In some cases, a high or low postprandial blood glucose reading can prevent methods, systems, and devices provided herein from adjusting the meal announcement buttons based on meals where one or more postprandial blood glucose readings indicate a mismatch between the dose and the meal. For example, if a user administers less insulin than recommended for a selected small meal and has one or more high postprandial blood glucose readings, methods, systems, and devices provided herein can ignore that administration for the personalization of the meal announcement buttons. In some cases, methods, systems, and devices provided herein can provide notices to a user if the user is consistently ignoring the recommended dosages in a way that causes the PWD to go high or low after a meal if the usage pattern indicates a mismatch between the user's mental model and the PWD's physiology and food consumption patterns. For example, if the user is consistently administering less insulin than recommended and consistently having high blood glucose readings after a meal, a notice may indicate to the user that the user should consider administering the recommended doses at meal times in order to achieve better glycemic control. Accordingly, in some cases, methods, systems, and devices provided herein can be designed to improve the match between the user's mental model and the PWD's physiology and food consumption patterns.
In some cases, a remote user interface device 110 can permit a user to manually enter a specific number of carbohydrates into a bolus calculator for a recommendation for a specific meal. In some cases, methods, systems, and devices can use repeated patterns of a user requesting the same meal size recommendation to update the size of a meal announcement button or to add another meal announcement button.
Dose Capture Pen Caps
Although pen caps 182, 184, 200, and 300 can use any suitable technology to estimate an insulin dosage,
Exemplary Use of Dose Capture Device/System
When a user administers insulin in step 660, the amount of insulin administered may differ from a recommended dosage and/or the recommendation may simply be that the user adjust their mental model of how much to administer for a meal, for example if the user does not make a meal announcement and doses insulin based on user screen 636. As shown in user screen 636, the dosage recommendation may be indicated in brackets to indicate an amount of insulin that should be used to correct for an elevated blood glucose level, and thus the user can add that to the amount of insulin that the user would ordinarily administer for a meal. Accordingly, methods, systems, and devices provided herein can infer the amount of carbohydrates eaten for a meal in the user's mental model based on an amount of insulin delivered by the user. For example, if a user retrieves an EGV from a glucose sensor or monitor in step 630 and sees a recommendation to take 3 units of Humalog in addition to what they would normally take, and then doses 10 units of Humalog, then the methods, systems, and devices provided herein can infer that the user ate a meal and estimate the size of the meal based on the bolus size. The estimated meal size can then be used by the system to further personalize meal announcement buttons (e.g., buttons 142-144, 221-223, and 321-323) and user-specific dosage parameters. Additionally, in some cases a user will announce a meal, but administer an amount of insulin that differs from the amount recommended, in which case methods, systems, and devices provided herein can either ignore the postprandial data for that administration for personalizing the meal announcement buttons (e.g., buttons 142-144, 221-223, and 321-323), but perhaps use the postprandial data for updating user-specific dosage parameters. For example, if a user is about to eat a meal that is between the user's mental model for a medium sized meal and the user's mental model for a large meal, the user might retrieve an EGV (e.g., in step 630) and look at a screen similar to user screen 636 to find out the amount for the correction dosage, and then announce a meal (e.g., in step 640) as a medium meal to see a screen similar to user screen 641 and then announce a meal again (e.g., conduct step 640 again) as a large meal to see a different recommendation, and then the user might deliver an amount of insulin between the two recommendations. Methods, systems, and devices provided herein can use data from a dose capture technique to estimate an amount of insulin actually delivered and use that insulin delivery data to determine an estimated size of each meal, regardless of whether the user announces the meal or follows the recommendation. Additionally, variations from the recommendations and postprandial glucose data can be used to determine adjustments to a number of carbohydrates represented by each meal announcement button e.g., buttons 142-144, 221-223, and 321-323) so that they match the user's mental model, as discussed above.
In many cases, a user will use their own mental model for administering boluses of insulin for meals and only use the system to determine a correction dose after obtaining an EGV (e.g., in step 630) and viewing a screen similar to user screens 631 or 636, which can in some cases indicate a correction dose only or might display two recommendations, (a) an amount to dose or suggestion to eat if they user is only seeking to correct a hyperglycemic or hypoglycemic condition and (b) a change to how much the user would typically dose if the user is eating. In some cases, the calculations can use different equations based on reducing a risk of a hypoglycemic condition. In some cases, a calculation for an amount to change the user's typical dose of insulin if the user is eating can incorporate adjustments based on detected patterns of the user over or under dosing insulin for meals in order to adjust for detected mismatches between the user's mental model and the PWD's physiology and food consumption patterns.
Wireless Communications and the Pairing Process
Referring back to
Passive and Active Information Gathering
Methods, devices, and systems provided herein can be adapted to gather information about insulin usage and user eating patterns passively without requiring the user to perform extra steps, but be available to help a user determine appropriate actions when called upon by the user. As such, methods, systems, and devices provided here can use dose capture technology in or attached to insulin pens to estimate amounts of insulin delivered to the person with diabetes (PWD). Additionally, estimated blood glucose values (EGVs) can be pushed or pulled to the pen caps and/or to the remote user interface device though wireless communications as discussed above, and be available to the user to help the user make insulin delivery decisions. In some cases, the glucose sensor or monitor 150 can be a flash glucose monitor that requires user interaction to retrieve an EGV. In some cases, a system including a flash glucose monitor can receive both a current EGV and past EGVs from an interrogation of the flash glucose monitor, which can be used by methods, devices, and systems provided herein to make therapy recommendations and to update user-specific dosage parameters.
In some cases, methods, devices, and systems can include user prompts to request information from the user or to request that the user obtain an EGV, based on risks to the user and/or to obtain data. For example, as discussed above, postprandial data can be used to update the meal announcement buttons. Additionally, postprandial data can be used to update other user-specific dosage parameters. Moreover, after a meal, a user is at an elevated risk of having a hyperglycemic or hypoglycemic condition. Accordingly, in some cases, methods, systems, and devices provided herein can request a user obtain an EGV. For example, in
Methods, devices, and systems provided herein can also seek feedback from a user regarding the user's mental model, especially if a user fails to announce a meal size. For example, in some cases, a user determining a dosage of quick-acting insulin may follow the steps shown in
Calculating and Updating Recommendations, User-Specific Dosage Parameters, and Active Insulin
Methods, devices, and systems provided herein can use any suitable technique for making recommendations, for updating user-specific dosage parameters (e.g., the person's ISF, CR, Total Daily LAI dosage, etc.), and for estimating amounts of unacted insulin (e.g., for calculating IOB). In some cases, the user-specific dosage parameters can vary depending on the time of day. In some cases, the user-specific dosage parameters can be determined using a fixed relationship between the user-specific dosage parameters. For example, in some cases such as a user having Type 1 Diabetes, a fixed relationship between Total Daily LAI and the PWD's carbohydrate-to-insulin ratio and the PWD's Insulin Sensitivity Factor can be based on fixed mathematical relationships. In some cases, the relationships may be determined by one of the plotted lines 915, 925, 935, 945, 955, 965, 975, or 985 shown in
Methods, systems, and devices, can, in some cases, make recommendations to the user to adjust dosages of LAI based on fasting blood glucose readings (e.g., blood glucose readings taken in the morning before the PWD has eaten). In some cases, methods, devices, and systems provided herein can increase by a set number of units (e.g., 0.5 units) based on fasting blood glucose readings being above a threshold and decrease the recommended dosage of LAI based on fasting blood glucose readings being below a different lower threshold. In some cases, methods, devices, and systems can provide recommendations regarding a dosage of LAI and quick-acting insulin (QAI) for if the user fails to deliver the LAI at an appropriate time.
Methods, devices, and systems provided herein can calculate a recommended correction bolus by subtracting a target blood glucose value from the EGV and dividing that number by the Insulin Sensitivity Factor (ISF) and then subtracting the IOB. Methods, devices, and systems provided herein can also calculate a recommended bolus for food consumption by dividing a number of carbohydrates associated with a food announcement button by a carbohydrate-to-insulin ratio (CR) stored for the PWD. Conversely, if a PWD delivers a bolus of insulin after calculating a correction bolus without entering a meal and that bolus differs from the recommended correction bolus, methods, systems, and devices provided herein can calculate an amount of inferred carbohydrates for the meal by subtracting the recommended correction bolus from the amount of insulin delivered and multiplying that number by a CR stored for the user. In other words, Inferred Carbs=(Bolus of Insulin delivered−Recommended Correction Bolus)*CR. Methods, systems, and devices provided herein can then use the calculated inferred carbs in calculating predicted blood glucose levels, which may be used to issue alarms or alerts (e.g., predictive hypoglycemic or predictive hyperglycemic alarms or alerts) to the PWD. In some cases, a Recommended Correction Bolus may be negative. In some cases, devices, systems, and methods provided herein can calculate an amount of inferred carbs by multiplying the bolus by the CR when the user does not input or retrieve an EGV and/or does not have the system calculate a recommended correction bolus. By having methods, systems, and devices infer a number of carbohydrates, methods, devices, and systems provided herein can match the user's mental model without requiring the user to enter data.
Systems for the Treatment of Type 2 Diabetes
In some cases, methods, systems, and devices provided herein can be used to treat a person with type 2 diabetes (PWT2D) and to personalize insulin therapy for the treatment of Type 2 Diabetes (T2D). For example, the system shown in
Type 2 Diabetes is often treated by slowly adding treatments. Initially, a PWT2D may be advised to control their diet and to exercise in order to prevent high blood glucose levels, which could be reviewed by logging blood glucose readings taken with a BGM. If diet and exercise is insufficient to achieve glycemic control, which may be defined by an HBA1C value of less than 7% and fasting/pre-meal blood glucose readings of less than 110 mg/dL (but may be personalized based on a number of factors), then the PWT2D may begin treatment of various drugs like GLP-1 RA or SGLT-2i or DPP-4i, which are designed to lower blood glucose levels. If those drugs do not achieve appropriate glycemic control, then the PWT2D may start insulin therapy using one or two injections of LAI, which or without the use of other drugs. Systems, devices, and methods provided herein can be used to assist PWT2Ds with the creating of a data log of blood glucose readings, documenting meals, and reminders of when to take post-meal blood glucose readings even if the PWT2D is not on insulin therapy.
If the PWT2D is taking LAI but not QAI for meals, methods and systems provided herein can be used to make adjustments to the LAI injections in addition to documenting BGM data and meals and issuing reminders. When starting systems and methods provided herein, the user and/or provider of healthcare services may set the initial amounts of LAI based on the PWT2D's previous LAI therapy. If the PWT2D is starting LAI therapy for the first time, the total units of LAI per day may be set at about 0.2 U/kg, or any amount between 0.1 and 0.3 U/kg, when the PWT2D starts the system. For example, if a PWT2D has an A1C of less than 8%, a provider of healthcare may typically set the total LAI therapy at somewhere between 0.1 and 0.2 U/kg. If a PWT2D has an A1C of greater than 8%, a provider of healthcare may typically set the total LAI therapy at somewhere between 0.2 and 0.3 U/kg. For example, a PWT2D weighing 100 kg and having an A1C of 8% might have a provider of healthcare set a total daily dose of LAI at 20 Units (e.g., 10 Units at 8 AM and 10 Units at 8 PM). In some cases, mobile application 10 can include an interface for the PWT2D or their provider of healthcare to enter an initial LAI therapy, which could be updated or adjusted later (both by the algorithm provided below or manually). In some cases, LAI therapy could be initially set and/or updated by a provider of healthcare in a remote web interface that connects to the mobile application through the cloud. In some cases, methods and systems provided herein may require that a qualified healthcare professional enter or confirm the initial LAI therapy.
Methods, devices, and systems provided herein can use and adjust the LAI therapy by tracking blood glucose data and LAI injections. In some cases, the LAI can be upwardly adjusted if an average fasting blood glucose reading for a period of time (e.g., 1 day, 2 days, 3 days, 5 days, 7 days, or more) exceeds a threshold. In some cases, the amount of the adjustment can depend on how much the average fasting blood glucose value exceeds a threshold. For example, in some cases a 3 day average fasting blood glucose value of between 110 and 140 mg/dL would result in an increase of 1 unit LAI per day, a 3 day average fasting blood glucose value of between 140 and 180 mg/dL would result in an increase of LAI by 10%, and a 3 day average fasting blood glucose value of at least 180 mg/dL would result in an increase of LAI by 20%. In some cases, the increase in percentage of LAI can be linearly proportional to the 2 or 3 day average over 110 mg/dL.
In some cases, the LAI can be downwardly adjusted if any blood glucose reading is below a threshold value, which could be hypoglycemia or indicate a risk for hypoglycemia. The decrease can be proportional to the low blood glucose reading. In some cases, if a blood glucose reading is between 40 and 70 mg/dL, the LAI would be decreased by between 10-20%, and a blood glucose reading of less than 40 mg/dL would result in a decrease of between 20-40%. In some cases, methods and systems provided here would decrease LAI 10% for a reading of about 70 mg/dL, decrease it by 20% for a reading of about 40 mg/dL, and decrease it by 40% for a reading of about 30 mg/dL or less.
Typically, if LAI therapy is achieving glycemic control, the system should not produce contradictory upward and downward adjustments. Moreover, glycemic control should result in the absence of hypoglycemia, prevent fasting and pre-meal blood glucose readings of greater than 110 mg/dL, and an A1C of less than 7%. If methods and systems fail to achieve glycemic control after a sufficient period of time (e.g., 1 month, 2 months, etc.), which can be preset or set by a provider of healthcare, the system can send a message to the provider of healthcare to indicate that additional therapy might be considered, which may include drugs like GLP-1 RA or SGLT-2i or DPP-4i or the use of both LAI and QAI therapy. If additional drugs other that QAI are added to the therapy, the system may continue to adjust LAI as described above and determine if glycemic control is achieved after a sufficient period of time (e.g., 1 month, 2 months, etc.).
If a PWT2D switches from LAI therapy alone to therapy using both LAI and QAI, a provider of healthcare can either switch to QAI for only some meals or for all meals. For example, in some cases a provider of healthcare may reduce LAI by 10% or 5 units and set a prandial QAI bolus for the largest meal at that 10% value or the value of 5 units, potentially adding prandial QAI boluses for additional meals if that fails to achieve glycemic control. In some cases, a provider of healthcare may decide to reduce LAI by 50% and set prandial QAI boluses at values to equal the reduction in LAI, perhaps estimating different amounts for different meals. Regardless of the amounts of LAI and prandial QAI boluses and times set by the provider of healthcare, methods and systems provided herein can make adjustments to both LAI and QAI injections based on blood glucose readings. The LAI total units per day could be decreased or increased using the same criteria discussed above for any fasting blood glucose reading. Each prandial QAI bolus can be adjusted by increasing it if a running average blood glucose reading after that meal is above a high threshold and decreasing if a post-meal blood glucose reading is below a low threshold. For example, if a post-meal blood glucose reading 2 hours after a meal is between 70 and 40 mg/dL, the prandial QAI bolus for that meal would be reduced by between 10 and 20%, and it would be reduced by between 20 and 40% if it is below 40 mg/dL. Post-meal blood glucose readings above 140 mg/dL could, for example, result in the system increasing the prandial QAI bolus for that meal by 10% or between 1-2 units of QAI for that meal. Accordingly, the systems and methods presented herein can personalize the size of prandial QAI meal boluses, which may be due to a PWT2D's typical meal size or variations in insulin sensitivity and carbohydrate-to-insulin ratios during the day. Systems provided herein could also issue notices to users if the prandial QAI boluses are producing highly variable post-meal blood glucose readings, indicating to the PWT2D that the meal sizes should remain approximately constant.
Systems, devices, and methods provided herein can also flag unusual circumstances for the user or the provider of healthcare and suggest additional tasks. For example, in some cases, a user may have a post-dinner blood glucose reading of 130 mg/dL, but wake up with a fasting blood glucose reading of greater than 160 mg/dL, which may indicate that the PWT2D may be experience a nighttime low followed by a rebound in blood glucose levels due to a biological response (e.g., the release of glucagon from the liver), thus the system may suggest an occasional additional blood glucose reading at night. A nighttime low may indicate a need to adjust the dinner QAI bolus or the units of LAI. In some cases, methods and systems provided herein may have data regarding a next appointment with a provider of healthcare and ask the PWT2D to take additional blood glucose measurements for a few days leading up to the appointment.
System-Based Inferences
In some cases, methods, devices or systems of the present disclosure may infer certain information by observing and/or analyzing data gathered in accordance with the present disclosure. For example, inferences may be made regarding whether or not a meal was consumed, a size of a meal consumed, whether or not a bolus of insulin was received, and/or a size of a bolus of insulin received.
In some cases, methods, devices or systems of the present disclosure may analyze historic blood glucose readings and note points when blood glucose levels rise, particularly around meal times. By observing rising blood glucose levels, an inference may be made regarding the consumption of a meal. Additionally or alternatively, using user-specific parameters (e.g., carbohydrate-to-insulin ratio (CR), insulin sensitivity factor (ISF), insulin-on-board (IOB), etc.) and/or historic data, a size of a meal may be inferred based on the amount of change in blood glucose levels and data gathered regarding meal sizes for the PWD. For example, if a known amount of insulin is repeatedly given for a PWD as a bolus for a meal and a known response is expected for an expected meal size, variations in that response may convey variations in the size of the meal.
In some cases, methods, devices or systems of the present disclosure may analyze historic blood glucose readings and note points when blood glucose levels decrease. For example, an inference may be made whether or not a user has received a bolus of insulin based on a decrease in blood glucose level based on an expected bolus associated with a meal. For example, an initial increase in blood glucose level around a meal time followed by a decrease in blood glucose level may indicate that a user did, in fact, receive a bolus for a meal. Additionally or alternatively, using user-specific parameters and/or historical data, a size of a bolus may be estimated. For example, if a meal size is known (or estimated) and a typical response is known (or expected) for a PWD, a decrease in blood glucose level may permit methods, devices or systems of the present disclosure to infer a bolus size. In some cases, methods, devices or systems of the present disclosure may use inferences to act as a security check to verify that a PWD received a bolus in association with a meal. For example, a PWD may use an insulin pen for boluses that is not in communication with other components of a system or device of the present disclosure, and such approaches may verify that a bolus was given for a meal.
In some cases, expected variations in blood glucose levels may incorporate the overlap of expected blood glucose levels due to LAI, QAI, and consumed carbohydrates. Such data may be inferred, read from one or more sensors or devices, or input by a user or PWD.
The embodiments described herein may include the use of a special-purpose or general-purpose computer including various computer hardware or software modules, as discussed in greater detail below.
Embodiments described herein may be implemented using computer-readable media for carrying or having computer-executable instructions or data structures stored thereon. Such computer-readable media may be any available media that may be accessed by a general-purpose or special-purpose computer. By way of example, and not limitation, such computer-readable media may include non-transitory computer-readable storage media including Random Access Memory (RAM), Read-Only Memory (ROM), Electrically Erasable Programmable Read-Only Memory (EEPROM), Compact Disc Read-Only Memory (CD-ROM) or other optical disk storage, magnetic disk storage or other magnetic storage devices, flash memory devices (e.g., solid state memory devices), or any other storage medium which may be used to carry or store desired program code in the form of computer-executable instructions or data structures and which may be accessed by a general-purpose or special-purpose computer. Combinations of the above may also be included within the scope of computer-readable media.
Computer-executable instructions comprise, for example, instructions and data which cause a general-purpose computer, special-purpose computer, or special-purpose processing device (e.g., one or more processors) to perform a certain function or group of functions. Although the subject matter has been described in language specific to structural features and/or methodological acts, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as example forms of implementing the claims.
Any ranges expressed herein (including in the claims) are considered to be given their broadest possible interpretation. For example, unless explicitly mentioned otherwise, ranges are to include their end points (e.g., a range of “between X and Y” would include X and Y). Additionally, ranges described using the terms “approximately” or “about” are to be understood to be given their broadest meaning consistent with the understanding of those skilled in the art. Additionally, the term approximately includes anything within 10%, or 5%, or within manufacturing or typical tolerances.
All examples and conditional language recited herein are intended for pedagogical objects to aid the reader in understanding the disclosure and the concepts contributed by the inventor to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Although embodiments of the present disclosure have been described in detail, it should be understood that the various changes, substitutions, and alterations could be made hereto without departing from the spirit and scope of the disclosure.
This application is a continuation of U.S. patent application Ser. No. 15/717,805, filed Sep. 27, 2017, now U.S. Pat. No. 10,426,896, issued Oct. 1, 2019, which claims the benefit of U.S. Patent Provisional Application No. 62/400,366, filed Sep. 27, 2016, the disclosure of each of which is hereby incorporated herein in its entirety by this reference.
Number | Name | Date | Kind |
---|---|---|---|
2605765 | Kollsman | Aug 1952 | A |
3886938 | Szabo et al. | Jun 1975 | A |
4077405 | Haerten et al. | Mar 1978 | A |
4231368 | Becker | Nov 1980 | A |
4265241 | Portner et al. | May 1981 | A |
4300554 | Hessberg et al. | Nov 1981 | A |
4313439 | Babb et al. | Feb 1982 | A |
4398908 | Siposs | Aug 1983 | A |
4435173 | Siposs et al. | Mar 1984 | A |
4443218 | Decant et al. | Apr 1984 | A |
4493704 | Beard et al. | Jan 1985 | A |
4529401 | Leslie et al. | Jul 1985 | A |
4681569 | Coble et al. | Jul 1987 | A |
4749109 | Kamen | Jun 1988 | A |
4838857 | Strowe et al. | Jun 1989 | A |
4850817 | Nason et al. | Jul 1989 | A |
5045064 | Idriss | Sep 1991 | A |
5088981 | Howson et al. | Feb 1992 | A |
5088990 | Hivale et al. | Feb 1992 | A |
D325781 | Moller-Jensen | Apr 1992 | S |
5190522 | Wojcicki et al. | Mar 1993 | A |
5225763 | Krohn et al. | Jul 1993 | A |
5250027 | Lewis et al. | Oct 1993 | A |
5261882 | Sealfon | Nov 1993 | A |
5314412 | Rex | May 1994 | A |
5335994 | Weynant | Aug 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5342180 | Daoud | Aug 1994 | A |
D351469 | Okamoto | Oct 1994 | S |
5389078 | Zalesky et al. | Feb 1995 | A |
5395340 | Lee | Mar 1995 | A |
5411487 | Castagna | May 1995 | A |
5545143 | Fischell et al. | Aug 1996 | A |
5551850 | Williamson et al. | Sep 1996 | A |
5554123 | Herskowitz | Sep 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5626566 | Petersen et al. | May 1997 | A |
5637095 | Nason et al. | Jun 1997 | A |
5640954 | Pfeiffer et al. | Jun 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5678571 | Brown | Oct 1997 | A |
5718562 | Lawless et al. | Feb 1998 | A |
D393264 | Leung | Apr 1998 | S |
5741216 | Hemmingsen et al. | Apr 1998 | A |
5766155 | Hyman et al. | Jun 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5816306 | Giacomel | Oct 1998 | A |
5852803 | Ashby et al. | Dec 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5918603 | Brown | Jul 1999 | A |
5919167 | Mulhauser et al. | Jul 1999 | A |
5925018 | Ungerstedt | Jul 1999 | A |
5928201 | Poulsen et al. | Jul 1999 | A |
5947934 | Hansen et al. | Sep 1999 | A |
5951530 | Steengaard et al. | Sep 1999 | A |
5957889 | Poulsen et al. | Sep 1999 | A |
5984894 | Poulsen et al. | Nov 1999 | A |
5984897 | Petersen et al. | Nov 1999 | A |
5997475 | Bortz | Dec 1999 | A |
6003736 | Ljunggren | Dec 1999 | A |
6010485 | Buch-Rasmussen et al. | Jan 2000 | A |
6032119 | Brown et al. | Feb 2000 | A |
6033377 | Rasmussen et al. | Mar 2000 | A |
6045537 | Klitmose | Apr 2000 | A |
D424036 | Arora et al. | May 2000 | S |
6056728 | Von Schuckmann | May 2000 | A |
6074372 | Hansen | Jun 2000 | A |
6110149 | Klitgaard et al. | Aug 2000 | A |
6156014 | Petersen et al. | Dec 2000 | A |
6171276 | Lippe et al. | Jan 2001 | B1 |
6231540 | Smedegaard | May 2001 | B1 |
6248067 | Causey et al. | Jun 2001 | B1 |
6248090 | Jensen et al. | Jun 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6277098 | Klitmose et al. | Aug 2001 | B1 |
6302855 | Lav et al. | Oct 2001 | B1 |
6302869 | Klitgaard | Oct 2001 | B1 |
6354996 | Drinan et al. | Mar 2002 | B1 |
6368314 | Kipfer et al. | Apr 2002 | B1 |
6375638 | Nason et al. | Apr 2002 | B2 |
6379339 | Klitgaard et al. | Apr 2002 | B1 |
6381496 | Meadows et al. | Apr 2002 | B1 |
6404098 | Kayama et al. | Jun 2002 | B1 |
D460053 | Choi | Jul 2002 | S |
6427088 | Bowman et al. | Jul 2002 | B1 |
D461241 | Moberg et al. | Aug 2002 | S |
D461891 | Moberg | Aug 2002 | S |
6436072 | Kullas et al. | Aug 2002 | B1 |
6461331 | Van Antwerp | Oct 2002 | B1 |
6474219 | Klitmose et al. | Nov 2002 | B2 |
6485461 | Mason et al. | Nov 2002 | B1 |
6508788 | Preuthun | Jan 2003 | B2 |
6524280 | Hansen et al. | Feb 2003 | B2 |
6533183 | Aasmul et al. | Mar 2003 | B2 |
6537251 | Klitmose | Mar 2003 | B2 |
6540672 | Simonsen et al. | Apr 2003 | B1 |
6544229 | Danby et al. | Apr 2003 | B1 |
6547764 | Larsen et al. | Apr 2003 | B2 |
6551276 | Mann et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6554800 | Nezhadian et al. | Apr 2003 | B1 |
6558320 | Causey et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6562001 | Lebel et al. | May 2003 | B2 |
6562011 | Buch-Rasmussen et al. | May 2003 | B1 |
6564105 | Starkweather et al. | May 2003 | B2 |
6569126 | Poulsen et al. | May 2003 | B1 |
6571128 | Lebel et al. | May 2003 | B2 |
6577899 | Lebel et al. | Jun 2003 | B2 |
6582404 | Klitgaard et al. | Jun 2003 | B1 |
6585644 | Lebel et al. | Jul 2003 | B2 |
6585699 | Ljunggreen et al. | Jul 2003 | B2 |
6589229 | Connelly et al. | Jul 2003 | B1 |
6605067 | Larsen | Aug 2003 | B1 |
6613019 | Munk | Sep 2003 | B2 |
6641533 | Causey et al. | Nov 2003 | B2 |
6648821 | Lebel et al. | Nov 2003 | B2 |
6650951 | Jones et al. | Nov 2003 | B1 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6659948 | Lebel et al. | Dec 2003 | B2 |
6659978 | Kasuga et al. | Dec 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6663602 | Schmidt | Dec 2003 | B2 |
6668196 | Villegas et al. | Dec 2003 | B1 |
6669669 | Flaherty et al. | Dec 2003 | B2 |
6687546 | Lebel et al. | Feb 2004 | B2 |
6690192 | Wing | Feb 2004 | B1 |
6691043 | Ribeiro, Jr. | Feb 2004 | B2 |
6692457 | Flaherty | Feb 2004 | B2 |
6692472 | Hansen et al. | Feb 2004 | B2 |
6694191 | Starkweather et al. | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6702779 | Connelly et al. | Mar 2004 | B2 |
6715516 | Ohms et al. | Apr 2004 | B2 |
6716198 | Larsen | Apr 2004 | B2 |
6723072 | Flaherty et al. | Apr 2004 | B2 |
6733446 | Lebel et al. | May 2004 | B2 |
6736796 | Shekalim | May 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6740072 | Starkweather et al. | May 2004 | B2 |
6740075 | Lebel et al. | May 2004 | B2 |
6744350 | Blomquist | Jun 2004 | B2 |
6749587 | Flaherty | Jun 2004 | B2 |
6752787 | Causey et al. | Jun 2004 | B1 |
6758810 | Lebel et al. | Jul 2004 | B2 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6780156 | Haueter et al. | Aug 2004 | B2 |
6786246 | Ohms et al. | Sep 2004 | B2 |
6786890 | Preuthun et al. | Sep 2004 | B2 |
6796970 | Klitmose et al. | Sep 2004 | B1 |
6799149 | Hartlaub | Sep 2004 | B2 |
6809653 | Mann et al. | Oct 2004 | B1 |
6810290 | Lebel et al. | Oct 2004 | B2 |
6811533 | Lebel et al. | Nov 2004 | B2 |
6811534 | Bowman et al. | Nov 2004 | B2 |
6813519 | Lebel et al. | Nov 2004 | B2 |
6827702 | Lebel et al. | Dec 2004 | B2 |
6830558 | Flaherty et al. | Dec 2004 | B2 |
6852104 | Blomquist | Feb 2005 | B2 |
6854620 | Ramey | Feb 2005 | B2 |
6854653 | Eilersen | Feb 2005 | B2 |
6855129 | Jensen et al. | Feb 2005 | B2 |
6872200 | Mann et al. | Mar 2005 | B2 |
6873268 | Lebel et al. | Mar 2005 | B2 |
6878132 | Kipfer | Apr 2005 | B2 |
6893415 | Madsen et al. | May 2005 | B2 |
6899695 | Herrera | May 2005 | B2 |
6899699 | Enggaard | May 2005 | B2 |
6922590 | Whitehurst | Jul 2005 | B1 |
6936006 | Sabra | Aug 2005 | B2 |
6936029 | Mann et al. | Aug 2005 | B2 |
6945961 | Miller et al. | Sep 2005 | B2 |
6948918 | Hansen | Sep 2005 | B2 |
6950708 | Bowman et al. | Sep 2005 | B2 |
6956572 | Zaleski | Oct 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6979326 | Mann et al. | Dec 2005 | B2 |
6997911 | Klitmose | Feb 2006 | B2 |
6997920 | Mann et al. | Feb 2006 | B2 |
7005078 | Van et al. | Feb 2006 | B2 |
7008399 | Larsen et al. | Mar 2006 | B2 |
7014625 | Bengtsson | Mar 2006 | B2 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7025743 | Mann et al. | Apr 2006 | B2 |
7029455 | Flaherty | Apr 2006 | B2 |
7054836 | Christensen et al. | May 2006 | B2 |
7096431 | Tambata et al. | Aug 2006 | B2 |
7104972 | Moller et al. | Sep 2006 | B2 |
7109878 | Mann et al. | Sep 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7133329 | Skyggebjerg et al. | Nov 2006 | B2 |
7232423 | Mernoee | Jun 2007 | B2 |
D545837 | Haldimann et al. | Jul 2007 | S |
7241265 | Cummings et al. | Jul 2007 | B2 |
D550227 | Sato et al. | Sep 2007 | S |
D553625 | Burns et al. | Oct 2007 | S |
D554140 | Armendariz | Oct 2007 | S |
7291107 | Hellwig et al. | Nov 2007 | B2 |
7343197 | Shusterman | Mar 2008 | B2 |
7454359 | Rosenfeld et al. | Nov 2008 | B2 |
7479949 | Jobs et al. | Jan 2009 | B2 |
D592223 | Neuhaus | May 2009 | S |
7534226 | Mernoe et al. | May 2009 | B2 |
7553281 | Hellwig et al. | Jun 2009 | B2 |
7555727 | Hawkins et al. | Jun 2009 | B2 |
7570980 | Ginsberg | Aug 2009 | B2 |
D600341 | Loerwald | Sep 2009 | S |
D603421 | Ebeling et al. | Nov 2009 | S |
D607099 | Loerwald | Dec 2009 | S |
7647237 | Malave et al. | Jan 2010 | B2 |
D614587 | Yodfat et al. | Apr 2010 | S |
7695434 | Malecha | Apr 2010 | B2 |
7708717 | Estes et al. | May 2010 | B2 |
7717903 | Estes et al. | May 2010 | B2 |
7751907 | Blomquist | Jul 2010 | B2 |
D623753 | Saffer et al. | Sep 2010 | S |
7789859 | Estes et al. | Sep 2010 | B2 |
D628107 | Lee | Nov 2010 | S |
7828528 | Estes et al. | Nov 2010 | B2 |
7837647 | Estes et al. | Nov 2010 | B2 |
7850641 | Lebel et al. | Dec 2010 | B2 |
7871376 | Brown | Jan 2011 | B2 |
D632699 | Judy et al. | Feb 2011 | S |
7878975 | Liljeryd et al. | Feb 2011 | B2 |
7887512 | Estes et al. | Feb 2011 | B2 |
7931613 | Haueter et al. | Apr 2011 | B2 |
7938797 | Estes | May 2011 | B2 |
D640269 | Chen | Jun 2011 | S |
7956845 | Lee | Jun 2011 | B2 |
D642191 | Barnett et al. | Jul 2011 | S |
D644242 | Matas | Aug 2011 | S |
D644243 | Matas | Aug 2011 | S |
8012119 | Estes et al. | Sep 2011 | B2 |
D648804 | Coulter | Nov 2011 | S |
D652426 | Anzures | Jan 2012 | S |
8132101 | Buck et al. | Mar 2012 | B2 |
D656950 | Shallcross et al. | Apr 2012 | S |
8156070 | Buck et al. | Apr 2012 | B2 |
D660315 | Anzures | May 2012 | S |
D661701 | Brown et al. | Jun 2012 | S |
8202249 | Iio et al. | Jun 2012 | B2 |
8217946 | Halpern et al. | Jul 2012 | B2 |
8219222 | Blomquist | Jul 2012 | B2 |
8221345 | Blomquist | Jul 2012 | B2 |
8221359 | Kristensen et al. | Jul 2012 | B2 |
8231562 | Buck et al. | Jul 2012 | B2 |
D665409 | Gupta et al. | Aug 2012 | S |
8237715 | Buck et al. | Aug 2012 | B2 |
8250483 | Blomquist | Aug 2012 | B2 |
8257652 | Drucker et al. | Sep 2012 | B2 |
8257653 | Drucker et al. | Sep 2012 | B2 |
8262616 | Grant et al. | Sep 2012 | B2 |
8273296 | Drucker et al. | Sep 2012 | B2 |
D669165 | Estes et al. | Oct 2012 | S |
D669166 | Estes et al. | Oct 2012 | S |
D669167 | Estes et al. | Oct 2012 | S |
8279226 | Krieftewirth | Oct 2012 | B2 |
8310415 | Mclaughlin et al. | Nov 2012 | B2 |
8337469 | Eberhart et al. | Dec 2012 | B2 |
D674405 | Guastella et al. | Jan 2013 | S |
8357091 | Say et al. | Jan 2013 | B2 |
8365065 | Gejdos et al. | Jan 2013 | B2 |
8372005 | Say et al. | Feb 2013 | B2 |
D682289 | Dijulio et al. | May 2013 | S |
D682304 | Mierau et al. | May 2013 | S |
D682305 | Mierau et al. | May 2013 | S |
8439834 | Schmelzeisen-Redeker et al. | May 2013 | B2 |
D683738 | Wujcik et al. | Jun 2013 | S |
D687062 | Gardner et al. | Jul 2013 | S |
D687541 | Estes et al. | Aug 2013 | S |
8514086 | Harper et al. | Aug 2013 | B2 |
D689087 | Fymat | Sep 2013 | S |
D689090 | Impas et al. | Sep 2013 | S |
D689523 | Galbraith et al. | Sep 2013 | S |
D689874 | Brinda et al. | Sep 2013 | S |
8529838 | Drucker et al. | Sep 2013 | B2 |
8529839 | Drucker et al. | Sep 2013 | B2 |
8529841 | Drucker et al. | Sep 2013 | B2 |
D690717 | Thomsen et al. | Oct 2013 | S |
D690718 | Thomsen et al. | Oct 2013 | S |
D691258 | Estes et al. | Oct 2013 | S |
D691259 | Estes et al. | Oct 2013 | S |
D693114 | Lemanski, Sr. | Nov 2013 | S |
D693365 | Gardner et al. | Nov 2013 | S |
D694262 | Jang et al. | Nov 2013 | S |
8579815 | Galley et al. | Nov 2013 | B2 |
8601005 | Bousamra et al. | Dec 2013 | B2 |
8615366 | Galley et al. | Dec 2013 | B2 |
D697204 | Maier et al. | Jan 2014 | S |
D697519 | Thomsen et al. | Jan 2014 | S |
8622906 | Say et al. | Jan 2014 | B2 |
D698808 | Funabashi et al. | Feb 2014 | S |
D699741 | Wantland et al. | Feb 2014 | S |
8657779 | Blomquist | Feb 2014 | B2 |
D701879 | Foit et al. | Apr 2014 | S |
D702258 | Wantland et al. | Apr 2014 | S |
D705261 | Holz et al. | May 2014 | S |
8719945 | Birtwhistle et al. | May 2014 | B2 |
8756074 | Brzustowicz | Jun 2014 | B2 |
8761940 | Long et al. | Jun 2014 | B2 |
D709080 | Kim | Jul 2014 | S |
D709183 | Kemlein | Jul 2014 | S |
D709917 | Faulkner et al. | Jul 2014 | S |
8774887 | Say et al. | Jul 2014 | B2 |
8816862 | Harper et al. | Aug 2014 | B2 |
8839106 | Lee et al. | Sep 2014 | B2 |
D714816 | Varon | Oct 2014 | S |
D715835 | Montgomery et al. | Oct 2014 | S |
D716340 | Bresin et al. | Oct 2014 | S |
D717822 | Brotman et al. | Nov 2014 | S |
D717823 | Brotman et al. | Nov 2014 | S |
D717830 | Brinda et al. | Nov 2014 | S |
D718438 | Davis et al. | Nov 2014 | S |
8895315 | Batman et al. | Nov 2014 | B2 |
D719186 | Kim | Dec 2014 | S |
8929823 | Mears et al. | Jan 2015 | B2 |
8961465 | Blomquist | Feb 2015 | B2 |
D724616 | Jou | Mar 2015 | S |
8992464 | Bashan et al. | Mar 2015 | B2 |
D727336 | Allison et al. | Apr 2015 | S |
9008803 | Blomquist | Apr 2015 | B2 |
9022996 | Eberhart et al. | May 2015 | B2 |
9033877 | Werner et al. | May 2015 | B2 |
9041730 | Johnson et al. | May 2015 | B2 |
D730929 | Yu et al. | Jun 2015 | S |
D731525 | Myers | Jun 2015 | S |
D733175 | Bae | Jun 2015 | S |
D733179 | Kwon | Jun 2015 | S |
9050409 | Haueter et al. | Jun 2015 | B2 |
9056165 | Steil et al. | Jun 2015 | B2 |
9072477 | Say et al. | Jul 2015 | B2 |
9076107 | Cameron et al. | Jul 2015 | B2 |
D736792 | Brinda et al. | Aug 2015 | S |
D737278 | Shin et al. | Aug 2015 | S |
D738907 | Cabrera-Cordon et al. | Sep 2015 | S |
D738913 | Cabrera-Cordon et al. | Sep 2015 | S |
D738914 | Torres et al. | Sep 2015 | S |
D739878 | Baxley | Sep 2015 | S |
9134823 | Grant et al. | Sep 2015 | B2 |
9136939 | Galley et al. | Sep 2015 | B2 |
9144204 | Redmond et al. | Sep 2015 | B2 |
D741891 | Gardner et al. | Oct 2015 | S |
9159148 | Boyer et al. | Oct 2015 | B2 |
9171343 | Fischell | Oct 2015 | B1 |
D743435 | Herold et al. | Nov 2015 | S |
9186113 | Harper et al. | Nov 2015 | B2 |
D744505 | Wilberding et al. | Dec 2015 | S |
D745050 | Kwon | Dec 2015 | S |
D745543 | Kim et al. | Dec 2015 | S |
D746314 | Jung et al. | Dec 2015 | S |
9198623 | Fern et al. | Dec 2015 | B2 |
D746848 | Bovet et al. | Jan 2016 | S |
D748646 | Kim et al. | Feb 2016 | S |
D749097 | Zou et al. | Feb 2016 | S |
D750663 | Mariet et al. | Mar 2016 | S |
D751081 | Kim et al. | Mar 2016 | S |
D751090 | Hu et al. | Mar 2016 | S |
D751585 | Kaufthal et al. | Mar 2016 | S |
D751586 | Kaufthal et al. | Mar 2016 | S |
D752604 | Zhang | Mar 2016 | S |
D752736 | Chandrasenan et al. | Mar 2016 | S |
D753139 | Bovet | Apr 2016 | S |
D753177 | Mierau et al. | Apr 2016 | S |
D753685 | Zimmerman et al. | Apr 2016 | S |
D754150 | Oh et al. | Apr 2016 | S |
D754670 | Park | Apr 2016 | S |
D754685 | Carlton et al. | Apr 2016 | S |
D754689 | Lee | Apr 2016 | S |
D754713 | Zhang et al. | Apr 2016 | S |
D754714 | Zhang et al. | Apr 2016 | S |
D755206 | Lee et al. | May 2016 | S |
D755830 | Chaudhri et al. | May 2016 | S |
D757026 | Lim et al. | May 2016 | S |
D757047 | Cornwell et al. | May 2016 | S |
D758433 | Lee et al. | Jun 2016 | S |
D760752 | Anzures et al. | Jul 2016 | S |
D761843 | Kim | Jul 2016 | S |
D762234 | Li et al. | Jul 2016 | S |
D762675 | Lim et al. | Aug 2016 | S |
D763285 | Chan et al. | Aug 2016 | S |
D763860 | Sunshine et al. | Aug 2016 | S |
D763921 | Dharwada et al. | Aug 2016 | S |
D765092 | Chaudhri et al. | Aug 2016 | S |
D765710 | Anzures et al. | Sep 2016 | S |
D766257 | Zhang et al. | Sep 2016 | S |
D766424 | Anderson et al. | Sep 2016 | S |
D768144 | Kim et al. | Oct 2016 | S |
D768687 | Bae et al. | Oct 2016 | S |
D769314 | Piroddi et al. | Oct 2016 | S |
D769322 | Rajeswaran et al. | Oct 2016 | S |
D769325 | Casalegno et al. | Oct 2016 | S |
D771672 | Tanabe et al. | Nov 2016 | S |
D772241 | Capano | Nov 2016 | S |
D772924 | Begin et al. | Nov 2016 | S |
D773510 | Foss et al. | Dec 2016 | S |
D776137 | Chaudhri et al. | Jan 2017 | S |
D776253 | Li | Jan 2017 | S |
D776702 | Huang et al. | Jan 2017 | S |
D777200 | Luo et al. | Jan 2017 | S |
D777204 | Lee et al. | Jan 2017 | S |
D777735 | Kim et al. | Jan 2017 | S |
D777906 | Anderson et al. | Jan 2017 | S |
D781305 | Lau | Mar 2017 | S |
D781908 | Bhandari et al. | Mar 2017 | S |
D783652 | Guan et al. | Apr 2017 | S |
D784372 | Kovchiy | Apr 2017 | S |
D786266 | Van et al. | May 2017 | S |
D786270 | Barry et al. | May 2017 | S |
D788138 | Lee et al. | May 2017 | S |
D788140 | Hemsley et al. | May 2017 | S |
D788145 | Sullivan et al. | May 2017 | S |
D788808 | Chaudhri et al. | Jun 2017 | S |
D789419 | Chaudhri et al. | Jun 2017 | S |
D790562 | Nageli et al. | Jun 2017 | S |
D790583 | Kay et al. | Jun 2017 | S |
D791806 | Brewington et al. | Jul 2017 | S |
9707336 | Dang et al. | Jul 2017 | B2 |
D794649 | Niijima et al. | Aug 2017 | S |
D795284 | Miller et al. | Aug 2017 | S |
D795294 | Faulkner et al. | Aug 2017 | S |
9717849 | Mhatre et al. | Aug 2017 | B2 |
D797123 | Lee et al. | Sep 2017 | S |
D797771 | Caporal et al. | Sep 2017 | S |
D797772 | Mizono et al. | Sep 2017 | S |
D797788 | Havranek, Jr. | Sep 2017 | S |
D798318 | Ferguson et al. | Sep 2017 | S |
D798895 | Kim et al. | Oct 2017 | S |
D799536 | Eder | Oct 2017 | S |
D800757 | Mullen et al. | Oct 2017 | S |
D801519 | Sabin et al. | Oct 2017 | S |
D801990 | Reissner et al. | Nov 2017 | S |
D802607 | Apodaca et al. | Nov 2017 | S |
D803850 | Chang et al. | Nov 2017 | S |
D804505 | Hoffman et al. | Dec 2017 | S |
D804516 | Dye et al. | Dec 2017 | S |
D805541 | Juliano | Dec 2017 | S |
D806117 | Springer | Dec 2017 | S |
D806748 | Van et al. | Jan 2018 | S |
D806749 | Van et al. | Jan 2018 | S |
D806750 | Van et al. | Jan 2018 | S |
D808417 | Mander et al. | Jan 2018 | S |
D808974 | Chiappone et al. | Jan 2018 | S |
D809134 | Crothall | Jan 2018 | S |
9878097 | Estes | Jan 2018 | B2 |
D809535 | Park et al. | Feb 2018 | S |
D810095 | Vali et al. | Feb 2018 | S |
D812072 | Hoffman | Mar 2018 | S |
D815665 | Li et al. | Apr 2018 | S |
D816093 | Mazur et al. | Apr 2018 | S |
9931454 | Lo et al. | Apr 2018 | B2 |
D816708 | Riedel et al. | May 2018 | S |
D816709 | Riedel et al. | May 2018 | S |
D816713 | Kang | May 2018 | S |
D819065 | Xie et al. | May 2018 | S |
D819067 | Behzadi et al. | May 2018 | S |
D819646 | Jow et al. | Jun 2018 | S |
D820304 | Coffman et al. | Jun 2018 | S |
D821437 | Chaudhri et al. | Jun 2018 | S |
D822708 | Ghosh | Jul 2018 | S |
D823859 | Boyd | Jul 2018 | S |
D826969 | Goyette et al. | Aug 2018 | S |
D828375 | Mok et al. | Sep 2018 | S |
D828377 | Dhide | Sep 2018 | S |
D830385 | Lepine et al. | Oct 2018 | S |
D835658 | Chan et al. | Dec 2018 | S |
D835659 | Anzures et al. | Dec 2018 | S |
D837809 | Kagatsume et al. | Jan 2019 | S |
D839287 | Hersh et al. | Jan 2019 | S |
D839294 | Mazlish et al. | Jan 2019 | S |
10263802 | Burns et al. | Apr 2019 | B2 |
D852816 | Baekelandt et al. | Jul 2019 | S |
D852817 | Aoshima | Jul 2019 | S |
D852837 | Mazlish et al. | Jul 2019 | S |
D853441 | Khandelwal | Jul 2019 | S |
D857724 | Clediere et al. | Aug 2019 | S |
D858566 | Bacchus | Sep 2019 | S |
D858567 | Bacchus | Sep 2019 | S |
10410538 | Simpson | Sep 2019 | B2 |
D863343 | Mazlish et al. | Oct 2019 | S |
D864239 | Hisada et al. | Oct 2019 | S |
10426896 | Desborough et al. | Oct 2019 | B2 |
D865813 | Lee et al. | Nov 2019 | S |
D866584 | Burroughs et al. | Nov 2019 | S |
D867601 | Henry et al. | Nov 2019 | S |
D870767 | Villafane | Dec 2019 | S |
D875111 | Clediere | Feb 2020 | S |
D875124 | Yan | Feb 2020 | S |
10572107 | Beebe et al. | Feb 2020 | B1 |
D879118 | Chen et al. | Mar 2020 | S |
D880497 | Boyd | Apr 2020 | S |
D883319 | Caro et al. | May 2020 | S |
D884007 | Uppala et al. | May 2020 | S |
D884716 | Tan et al. | May 2020 | S |
D886850 | Kim et al. | Jun 2020 | S |
D888748 | Valladares et al. | Jun 2020 | S |
D890206 | Felkins et al. | Jul 2020 | S |
D910063 | Brooks | Feb 2021 | S |
D910654 | Eder | Feb 2021 | S |
D910669 | Wuqiang | Feb 2021 | S |
D920349 | Clements et al. | May 2021 | S |
D927527 | Bragdon et al. | Aug 2021 | S |
D931898 | Demar | Sep 2021 | S |
D937312 | Ding et al. | Nov 2021 | S |
D939570 | Dye et al. | Dec 2021 | S |
D940156 | Butcher et al. | Jan 2022 | S |
D944772 | Kim | Mar 2022 | S |
D944824 | Wang et al. | Mar 2022 | S |
20010041869 | Causey et al. | Nov 2001 | A1 |
20010056262 | Cabiri et al. | Dec 2001 | A1 |
20020004651 | Ljunggreen et al. | Jan 2002 | A1 |
20020007154 | Hansen et al. | Jan 2002 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020091358 | Klitmose | Jul 2002 | A1 |
20020126036 | Flaherty et al. | Sep 2002 | A1 |
20020175931 | Holtz et al. | Nov 2002 | A1 |
20020177810 | Reilly et al. | Nov 2002 | A1 |
20030028089 | Galley | Feb 2003 | A1 |
20030055380 | Flaherty | Mar 2003 | A1 |
20030065308 | Lebel et al. | Apr 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030167035 | Flaherty et al. | Sep 2003 | A1 |
20030198558 | Nason et al. | Oct 2003 | A1 |
20030199825 | Flaherty | Oct 2003 | A1 |
20030216683 | Shekalim | Nov 2003 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040019325 | Shekalim | Jan 2004 | A1 |
20040064088 | Gorman et al. | Apr 2004 | A1 |
20040064096 | Flaherty et al. | Apr 2004 | A1 |
20040078028 | Flaherty et al. | Apr 2004 | A1 |
20040087894 | Flaherty | May 2004 | A1 |
20040092865 | Flaherty et al. | May 2004 | A1 |
20040092878 | Flaherty | May 2004 | A1 |
20040093331 | Garner et al. | May 2004 | A1 |
20040116866 | Gorman et al. | Jun 2004 | A1 |
20040127844 | Flaherty | Jul 2004 | A1 |
20040153032 | Garribotto et al. | Aug 2004 | A1 |
20040153257 | Munk | Aug 2004 | A1 |
20040171983 | Sparks et al. | Sep 2004 | A1 |
20040176727 | Shekalim | Sep 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040220551 | Flaherty et al. | Nov 2004 | A1 |
20040235446 | Flaherty et al. | Nov 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050021005 | Flaherty et al. | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050038674 | Braig et al. | Feb 2005 | A1 |
20050044500 | Orimoto et al. | Feb 2005 | A1 |
20050065760 | Murtfeldt et al. | Mar 2005 | A1 |
20050090808 | Malave et al. | Apr 2005 | A1 |
20050090851 | Devlin | Apr 2005 | A1 |
20050095063 | Fathallah et al. | May 2005 | A1 |
20050114374 | Juszkiewicz et al. | May 2005 | A1 |
20050160858 | Mernoe | Jul 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050182366 | Vogt et al. | Aug 2005 | A1 |
20050192494 | Ginsberg | Sep 2005 | A1 |
20050192561 | Mernoe | Sep 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050215982 | Malave et al. | Sep 2005 | A1 |
20050222645 | Malave et al. | Oct 2005 | A1 |
20050234404 | Vilks et al. | Oct 2005 | A1 |
20050238507 | Diianni et al. | Oct 2005 | A1 |
20050245878 | Mernoe et al. | Nov 2005 | A1 |
20050251097 | Mernoe | Nov 2005 | A1 |
20050267402 | Stewart et al. | Dec 2005 | A1 |
20050273059 | Mernoe et al. | Dec 2005 | A1 |
20060041229 | Garibotto et al. | Feb 2006 | A1 |
20060069382 | Pedersen | Mar 2006 | A1 |
20060074381 | Malave et al. | Apr 2006 | A1 |
20060095014 | Ethelfeld | May 2006 | A1 |
20060135913 | Ethelfeld | Jun 2006 | A1 |
20060142698 | Ethelfeld | Jun 2006 | A1 |
20060151545 | Imhof et al. | Jul 2006 | A1 |
20060178633 | Garibotto et al. | Aug 2006 | A1 |
20060184119 | Remde et al. | Aug 2006 | A1 |
20060200073 | Radmer et al. | Sep 2006 | A1 |
20060206054 | Shekalim | Sep 2006 | A1 |
20060247581 | Pedersen et al. | Nov 2006 | A1 |
20060276771 | Galley et al. | Dec 2006 | A1 |
20070073228 | Mernoe et al. | Mar 2007 | A1 |
20070073235 | Estes et al. | Mar 2007 | A1 |
20070073236 | Mernoe et al. | Mar 2007 | A1 |
20070088271 | Richards | Apr 2007 | A1 |
20070106218 | Yodfat et al. | May 2007 | A1 |
20070124002 | Estes et al. | May 2007 | A1 |
20070156092 | Estes et al. | Jul 2007 | A1 |
20070167905 | Estes et al. | Jul 2007 | A1 |
20070167912 | Causey et al. | Jul 2007 | A1 |
20070171087 | Shimazu et al. | Jul 2007 | A1 |
20070179444 | Causey et al. | Aug 2007 | A1 |
20070213657 | Jennewine et al. | Sep 2007 | A1 |
20070239116 | Follman et al. | Oct 2007 | A1 |
20080051716 | Stutz | Feb 2008 | A1 |
20080059158 | Matsuo et al. | Mar 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080119705 | Patel et al. | May 2008 | A1 |
20080172026 | Blomquist | Jul 2008 | A1 |
20080201325 | Doniger et al. | Aug 2008 | A1 |
20080208627 | Skyggebjerg | Aug 2008 | A1 |
20080220752 | Forstall et al. | Sep 2008 | A1 |
20080262469 | Brister et al. | Oct 2008 | A1 |
20080287755 | Sass et al. | Nov 2008 | A1 |
20080287922 | Panduro | Nov 2008 | A1 |
20080294094 | Mhatre et al. | Nov 2008 | A1 |
20080294108 | Briones et al. | Nov 2008 | A1 |
20080294109 | Estes et al. | Nov 2008 | A1 |
20080294142 | Patel et al. | Nov 2008 | A1 |
20080300534 | Blomquist | Dec 2008 | A1 |
20080306434 | Dobbles et al. | Dec 2008 | A1 |
20080319383 | Byland et al. | Dec 2008 | A1 |
20090054750 | Jennewine | Feb 2009 | A1 |
20090058823 | Kocienda | Mar 2009 | A1 |
20090067989 | Estes et al. | Mar 2009 | A1 |
20090069745 | Estes et al. | Mar 2009 | A1 |
20090069746 | Miller et al. | Mar 2009 | A1 |
20090069749 | Miller et al. | Mar 2009 | A1 |
20090069784 | Estes et al. | Mar 2009 | A1 |
20090069785 | Miller et al. | Mar 2009 | A1 |
20090069787 | Estes et al. | Mar 2009 | A1 |
20090089710 | Wood et al. | Apr 2009 | A1 |
20090099523 | Grant et al. | Apr 2009 | A1 |
20090156990 | Wenger et al. | Jun 2009 | A1 |
20090164239 | Hayter et al. | Jun 2009 | A1 |
20090197635 | Kim et al. | Aug 2009 | A1 |
20090204421 | Guimaraes | Aug 2009 | A1 |
20090253970 | Bashan | Oct 2009 | A1 |
20090292247 | Basso et al. | Nov 2009 | A1 |
20100016700 | Sieh et al. | Jan 2010 | A1 |
20100048358 | Tchao et al. | Feb 2010 | A1 |
20100118037 | Sheikh et al. | May 2010 | A1 |
20100174266 | Estes | Jul 2010 | A1 |
20100273610 | Johnson | Oct 2010 | A1 |
20100280329 | Randloev et al. | Nov 2010 | A1 |
20100286601 | Yodfat et al. | Nov 2010 | A1 |
20100298765 | Budiman et al. | Nov 2010 | A1 |
20100305965 | Benjamin et al. | Dec 2010 | A1 |
20100315359 | Seong et al. | Dec 2010 | A1 |
20110009846 | Istoc et al. | Jan 2011 | A1 |
20110040247 | Mandro et al. | Feb 2011 | A1 |
20110092788 | Long et al. | Apr 2011 | A1 |
20110152657 | Bielawa et al. | Jun 2011 | A1 |
20110160555 | Reifman et al. | Jun 2011 | A1 |
20110201911 | Johnson et al. | Aug 2011 | A1 |
20110238520 | Selley | Sep 2011 | A1 |
20110273388 | Joo et al. | Nov 2011 | A1 |
20110313349 | Krulevitch et al. | Dec 2011 | A1 |
20110319322 | Bashan et al. | Dec 2011 | A1 |
20120022496 | Causey et al. | Jan 2012 | A1 |
20120053560 | Kawamura | Mar 2012 | A1 |
20120159328 | Millington et al. | Jun 2012 | A1 |
20120215201 | Brauker et al. | Aug 2012 | A1 |
20120226124 | Blomquist | Sep 2012 | A1 |
20120232520 | Sloan et al. | Sep 2012 | A1 |
20120238999 | Estes et al. | Sep 2012 | A1 |
20120330270 | Colton | Dec 2012 | A1 |
20130165901 | Ruchti et al. | Jun 2013 | A1 |
20130172710 | Mears et al. | Jul 2013 | A1 |
20130184547 | Taub | Jul 2013 | A1 |
20130245545 | Arnold et al. | Sep 2013 | A1 |
20130318439 | Landis et al. | Nov 2013 | A1 |
20130324941 | Mann et al. | Dec 2013 | A1 |
20130331659 | Koski et al. | Dec 2013 | A1 |
20130332952 | Anandpura et al. | Dec 2013 | A1 |
20130338453 | Duke et al. | Dec 2013 | A1 |
20140012117 | Mensinger et al. | Jan 2014 | A1 |
20140025400 | Galley et al. | Jan 2014 | A1 |
20140031786 | Kircher, Jr. et al. | Jan 2014 | A1 |
20140039383 | Dobbles et al. | Feb 2014 | A1 |
20140058749 | Galley et al. | Feb 2014 | A1 |
20140068487 | Steiger et al. | Mar 2014 | A1 |
20140073892 | Randloev et al. | Mar 2014 | A1 |
20140154987 | Lee et al. | Jun 2014 | A1 |
20140160078 | Seo et al. | Jun 2014 | A1 |
20140309615 | Mazlish | Oct 2014 | A1 |
20140317546 | Jacobson et al. | Oct 2014 | A1 |
20140344280 | Wei et al. | Nov 2014 | A1 |
20140358082 | Ohzawa | Dec 2014 | A1 |
20140380218 | Johnnie | Dec 2014 | A1 |
20150025498 | Estes | Jan 2015 | A1 |
20150067527 | Gardner et al. | Mar 2015 | A1 |
20150073337 | Saint et al. | Mar 2015 | A1 |
20150073754 | Okkonen | Mar 2015 | A1 |
20150080842 | Mathys | Mar 2015 | A1 |
20150112264 | Kamen et al. | Apr 2015 | A1 |
20150141912 | Estes | May 2015 | A1 |
20150173674 | Hayes et al. | Jun 2015 | A1 |
20150277722 | Masterson et al. | Oct 2015 | A1 |
20160000998 | Estes | Jan 2016 | A1 |
20160038675 | Estes et al. | Feb 2016 | A1 |
20160058939 | Brewer et al. | Mar 2016 | A1 |
20160072841 | Caporal et al. | Mar 2016 | A1 |
20160089491 | Smith | Mar 2016 | A1 |
20160110064 | Shapira | Apr 2016 | A1 |
20160139671 | Jun et al. | May 2016 | A1 |
20160235913 | Smith et al. | Aug 2016 | A1 |
20160250422 | Koch et al. | Sep 2016 | A1 |
20160317743 | Estes | Nov 2016 | A1 |
20160357371 | Lee | Dec 2016 | A1 |
20160361494 | Jurg et al. | Dec 2016 | A1 |
20170003848 | Wakayanagi et al. | Jan 2017 | A1 |
20170017374 | Herz | Jan 2017 | A1 |
20170049957 | Michaud | Feb 2017 | A1 |
20170056591 | Breton et al. | Mar 2017 | A1 |
20170100538 | Mhatre et al. | Apr 2017 | A1 |
20170165416 | Saint | Jun 2017 | A1 |
20170173262 | Veltz | Jun 2017 | A1 |
20170176952 | Misaki et al. | Jun 2017 | A1 |
20170189614 | Mazlish et al. | Jul 2017 | A1 |
20170193184 | Hayter et al. | Jul 2017 | A1 |
20170199985 | Mazlish et al. | Jul 2017 | A1 |
20170203030 | Brewer et al. | Jul 2017 | A1 |
20170203036 | Mazlish et al. | Jul 2017 | A1 |
20170203037 | Desborough et al. | Jul 2017 | A1 |
20170203038 | Desborough et al. | Jul 2017 | A1 |
20170203039 | Desborough et al. | Jul 2017 | A1 |
20170216524 | Haider et al. | Aug 2017 | A1 |
20170224910 | Yodfat et al. | Aug 2017 | A1 |
20170232195 | Desborough et al. | Aug 2017 | A1 |
20170242975 | Kahlbaugh | Aug 2017 | A1 |
20170255771 | Miyakawa | Sep 2017 | A1 |
20170316592 | Kamath et al. | Nov 2017 | A1 |
20170332952 | Desborough et al. | Nov 2017 | A1 |
20170348484 | Duke | Dec 2017 | A1 |
20170351842 | Booth et al. | Dec 2017 | A1 |
20180001006 | Schade et al. | Jan 2018 | A1 |
20180036495 | Searle et al. | Feb 2018 | A1 |
20180089395 | Desborough et al. | Mar 2018 | A1 |
20180101297 | Yang et al. | Apr 2018 | A1 |
20180133397 | Estes | May 2018 | A1 |
20180147362 | Arenas et al. | May 2018 | A1 |
20180150614 | Sokolovskyy et al. | May 2018 | A1 |
20180161499 | Al-Ali et al. | Jun 2018 | A1 |
20180200435 | Mazlish et al. | Jul 2018 | A1 |
20180200436 | Mazlish et al. | Jul 2018 | A1 |
20180200437 | Mazlish et al. | Jul 2018 | A1 |
20180200438 | Mazlish et al. | Jul 2018 | A1 |
20180200439 | Mazlish et al. | Jul 2018 | A1 |
20180200441 | Desborough et al. | Jul 2018 | A1 |
20180207380 | Lantz et al. | Jul 2018 | A1 |
20180361060 | Rosinko | Dec 2018 | A9 |
20190001067 | Berey et al. | Jan 2019 | A1 |
20190015024 | Desborough et al. | Jan 2019 | A1 |
20190175841 | Sjolund | Jun 2019 | A1 |
20190183434 | Sjolund et al. | Jun 2019 | A1 |
20190184111 | Sjolund et al. | Jun 2019 | A1 |
20190265871 | Eim et al. | Aug 2019 | A1 |
20190274624 | Mazlish et al. | Sep 2019 | A1 |
20190348166 | Booth et al. | Nov 2019 | A1 |
20200042166 | Burns et al. | Feb 2020 | A1 |
20200097131 | Bowden et al. | Mar 2020 | A1 |
20200201494 | Allington et al. | Jun 2020 | A1 |
20200236212 | Vinna et al. | Jul 2020 | A1 |
Number | Date | Country |
---|---|---|
2543545 | May 2005 | CA |
104620244 | May 2015 | CN |
19627619 | Jan 1998 | DE |
10236669 | Feb 2004 | DE |
000627617-0002 | Jan 2007 | EM |
000627617-0003 | Jan 2007 | EM |
000627617-0091 | Jan 2007 | EM |
0006276170001 | Jan 2007 | EM |
0006276170002 | Jan 2007 | EM |
0006276170003 | Jan 2007 | EM |
000732649-0001 | Jun 2007 | EM |
000732649-0002 | Jun 2007 | EM |
0007326490001 | Jun 2007 | EM |
0007326490002 | Jun 2007 | EM |
003126705-0091 | Jul 2016 | EM |
003126795-9992 | Jul 2016 | EM |
003126795-9993 | Jul 2016 | EM |
003126795-9994 | Jul 2016 | EM |
0031267050001 | Jul 2016 | EM |
0031267050002 | Jul 2016 | EM |
0031267050003 | Jul 2016 | EM |
0031267050004 | Jul 2016 | EM |
0062974 | Oct 1982 | EP |
0275213 | Jul 1988 | EP |
0496141 | Jul 1992 | EP |
0580723 | Feb 1994 | EP |
0612004 | Aug 1994 | EP |
0721358 | Jul 1996 | EP |
1045146 | Oct 2000 | EP |
1136698 | Sep 2001 | EP |
1177802 | Feb 2002 | EP |
1495775 | Jan 2005 | EP |
1527792 | May 2005 | EP |
1754498 | Feb 2007 | EP |
1818664 | Aug 2007 | EP |
2585252 | May 2013 | EP |
2585252 | Jan 1987 | FR |
0747701 | Apr 1956 | GB |
2218831 | Nov 1989 | GB |
9015928 | Dec 1990 | WO |
9509021 | Apr 1995 | WO |
9721457 | Jun 1997 | WO |
9804301 | Feb 1998 | WO |
9811927 | Mar 1998 | WO |
9857683 | Dec 1998 | WO |
9921596 | May 1999 | WO |
9939118 | Aug 1999 | WO |
9948546 | Sep 1999 | WO |
0172360 | Oct 2001 | WO |
0191822 | Dec 2001 | WO |
0191833 | Dec 2001 | WO |
0240083 | May 2002 | WO |
0257627 | Jul 2002 | WO |
0268015 | Sep 2002 | WO |
0284336 | Oct 2002 | WO |
2002100469 | Dec 2002 | WO |
0326726 | Apr 2003 | WO |
2003103763 | Dec 2003 | WO |
2004056412 | Jul 2004 | WO |
2004110526 | Dec 2004 | WO |
2005002652 | Jan 2005 | WO |
2005039673 | May 2005 | WO |
2005072794 | Aug 2005 | WO |
2005072795 | Aug 2005 | WO |
2006067217 | Jun 2006 | WO |
2006097453 | Sep 2006 | WO |
2006105792 | Oct 2006 | WO |
2006105793 | Oct 2006 | WO |
2006105794 | Oct 2006 | WO |
2007141786 | Dec 2007 | WO |
2011163450 | Dec 2011 | WO |
2016019192 | Feb 2016 | WO |
2017009724 | Jan 2017 | WO |
Entry |
---|
Owens et al., Run-to-Run Control of Blood Glucose Concentrations for People with Type 1 Diabetes Mellitus, IEEE 2006, pp. 996-1005. (Year: 2006). |
Eren-Oruklu et al., Adaptive Control Strategy for Regulation of Blood Glucose Levels in Patients with Type 1 Diabetes, ScienceDirect 2009, pp. 1333-1346. (Year: 2009). |
“Clean Toggle Button Navigation Menu PSD” Jan. 24, 2014, WeLoveSoLo, site visited Oct. 19, 2018: https://www.welovesolo.com/clean-toggle-button-navigation-menu-psd/. |
“Omnipod Horizon: Automated Glucose Control” Jun. 2017, 2 pages. |
Accu-Chek Spirit, “Pump Therapy Made for You,” Roche, 2006, 6 pages. |
Arrow Repeat. By Flaticon. Freepik.com. Date: 2014. Retrieved from Internet: <https://www.freepik com/free-icon/arrow-repeat_ 694329.htm#term=arrows&page=47&position=67> (Year: 2014). |
Arrows Curves Forming an Oval Shape. By Flaticon. Freepik.com. Date: 2015. Retrieved from Internet: <https://www.freepik.com/free-icon/arrows-curves-forming-an-oval-shape_746143.htm> (Year: 2015). |
Arrows, Couple, IOS 7 Interface Symbol. By Flaticon. Freepik.com. Date: 2015. Retrieved from Internet: <https://www.freepik.com/free-icon/arrows-couple-ios-7-interface-symbo_751266.htm#tterm=arrows&page=68&position=43> (Year: 2015). |
Baruah, Insulin Pens: The Modern Delivery Devices, Google Scholar 2011, pp. 38-40. (Year: 2011). |
Bhalla, Raveesh, Understanding Material Design Part II, Sep. 28, 2014, Medium.com [online], [site visited Apr. 11, 2018], Available from Internet: https://medium.eom/@raveeshbhalla/understanding-material-design-cf2d60a16de3 (Year: 2014). |
Bigfoot Biomedical Reveals its Automated Insulin Delivery System. diaTribe. Date published: Jan. 25, 2016 <https://diatribe.org/bigfoot-biomedical-reveals-its-automated-insulin-delivery-system>. |
Bode et al., Diabetes Management in the New Millennium Using Insulin Pump Therapy, Wiley Inter Science 2002, pp. 514-520. (Year: 2002). |
Collins and Lee, “Microfluidic flow transducer based on the measurement of electrical admittance,” Lab Chip, 2004,4:7-10. |
Curved Arrow to the Right. By Flaticon. Freepik.com. Date: 2015. Retrieved from Internet: 21 https://www.freepik.com/free-icon/curved-arrow-to-the-right 735735.htm#term=arrows&page=59&position=69> (Year: 2015). |
Dassau and Associates, 12-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1C and Hypoglycemia, Diabetes Care, Oct. 13, 2017. |
David A. Copp, Ravi Gondhalekar, and Joao P. Hespanha, Simultaneous Model Predictive Control and Moving Horizon Estimation for Blood Glucose Regulation in Type 1 Diabetes, Optimal Control Applications and Methods, Wiley InterScience, DOI: 10.1002/oca, pp. 1-15, Oct. 2016. |
Delaney, Chelsey, “4 apps for tracking your fertility” Jun. 6, 2016, Bedsider, site visited Oct. 19, 2018: https://www.bedsider.org/features/647-4-apps-for-tracking-your-fertility. |
Dreyfuss, Henry. Symbol Sourcebook. Van Nostrand Reinhold Company. Date published: 1984. Page 28. (Year: 1984). |
E. Salzsieder, G. Albrecht, E. Jutzi, and U. Fischer, Estimation of Individually Adapted Control Parameten for an Artificial Beta Cell, Biomedica Biochimica Acta. 43(5) pp. 585-596, May 1984. |
Fischer et al.. In Vivo Comparison of Different Algorithms for the Artificial Beta-Cell, Artificial Organs, 9(2), International Society for Artificial Organs, May 1985, New York. |
Guy A. Dumont, Feedback Control for Clinicians, Springer Science+Media, Apr. 12, 2013, New York. |
Hoskins, Mike, NEWS: Bigfoot Closed Loop, Jul. 17, 2017, Healthline.com [online], [visited Jan. 22, 2019]. Internet: https://web.archive.org/web/20170810052840/https://www.diabetesdaily.com/blog/bigfoot-biomedical-aims-to-take-multiple-daily-injections-to-the-next-level-with-timesulin-acquisition (Year: 2017). |
International Search Report for PCT Application No. PCT/US2017/053814, dated Jan. 4, 2018, 4 pages. |
Kuwayama, Yasaburo. Trademarks & Symbols. vol. 2: Symbolical Designs. Van Nostrand Reinhold Company. Date published: 1973. p. 136 (Year: 1973). |
Michele Schiavon, Chiara Dalla Man, Yogish C. Kudva, Ananda Basu, and Claudio Cobelli, Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor-Augmented Insulin Pump, Diabetes Care, vol. 37, pp. 1216-1223, May 2014. |
OmniPod Insulin Management System—Investor Relations—Press Release, Feb. 1, 2005, http://investors.insulel.com/phoenix.zhlml?c=209336&p=irol-newsArticle&ID=988708&highlight= 1 page. |
OmniPod Quick Start Guide, 2007, 2 pages. |
Patent Abstracts of Japan, vol. 1999, No. 04, and JP 11 010036, Apr. 30, 1999 and Jan. 19, 1999, Toray Ind. Inc. |
Pearson, Practical Aspect of Insulin Pen Devices, Journal of Diabetes Science and Technology 2010, pp. 522-531. (Year: 2010). |
Refresh Arrow Loop. By Flaticon. Freepik.com. Date:2014. Retrieved from Internet: <https://www.freepik.com/free-icon/refresh-arrow-loop_705291 .htm#term=arrows&page=49&position=43> (Year: 2014). |
Refreshing. By Flaticon. Freepik.com. Date: 2016. Retrieved from Internet: <https://www.freepik.com/free-icon/refreshing_807573. htm#term=arrows&page=26&position=26> (Year: 2016). |
Sara Krugman, Bionic Pancreas User Interface (3/4): Interface Details, Tidepool.org, Jul. 20, 2015. |
Sindaco et al., Use of the Short-acting Insulin Analogue Lispro in Intensive Treatment of Type 1 Diabetes Mellitus: Importance of Appropriate Replacement of Basal Insulin and Time-interval Injection-meal, Diabetic Medicine 1998, pp. 592-600. (Year: 1998). |
Smart et al., “Can children with type 1 diabetes and their caregivers estimate the carbohydrate content of meals and snacks?” Diabetic Medicine, 27, No. 3 (2010) pp. 38-353. |
Synchronise, IOS 7 Interface Symbol. By Flaticon. Freepik.com. Date: 2015. Retrieved from Internet: <https://www.freepik.com/free-icon/synchronise-ios-7-interface-symbol_751804.htm#term=arrows&page=69&position=14> (Year: 2015). |
T:slimx2 Insulin Pump User Guide, Tandem Diabetes Care, Jul. 22, 2016. |
The Medtronic Diabetes Connection, 2006, 6 pages. |
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2017/053814, dated Jan. 4, 2018, 8 pages. |
Xilas Temp Touch, “The latest in high-tech and convenient devices,” DOCNews, vol. 2, No. 7, Jul. 1, 2005, http://docnews.diabetesjoumals.ordlcgi/contenl/foll/2/7i 13, 3 pages. |
Zhang et al., Second Insulin Pump Safety Meeting: Summary Report, Journal of Diabetes Science and Technology 2010, pp. 488-493. (Year: 2010). |
“Medical Set.” iconfinder.com. Added Apr. 7, 2017. Accessed Jan. 27, 2020. Available online at URL: https://www.iconfinder.com/iconsets/medical-set-5 (Year: 2017). |
“Three icons—Ready, Set and Go” Nov. 29, 2015, depositphotos, site visited Apr. 21, 2020: https://depositphotos.com/91436542/stock-illustration-countdown-ready-set-go-colorful.html (Year: 2015). |
Ansyari, Nazurrudin. “Circle Badge Set.” iconfinder.com. Added Aug. 15, 2016. Accessed Jan. 27, 2020. Available online at URL: https://www.iconfinder.com/iconsets/ciicle-badge-set (Year: 2016). |
Bhalla, Reveesh, Understading Material Design Part II, Sep. 28, 2014, Medium.com [online], [site visited Apr. 11, 2018], Available from Internet: https://medium.com/@raveeshbhalla/understanding-material-design-cf2d60a16de3 (Year: 2014). |
Bigfoot Biomedical Reveals its Automated Insulin Delivery System. diaTribe. Date published: Jan. 25, 2016 <https://diatrive.org/bigfoot-biomedical-reveals-its-automated-insulin-delivery-system>. |
Centers for Disease Control and Prevention, Number (in Millions) of Adults with Diabetes by Diabetes Medication Status, United States, 1997-2011, http://www.cdc.gov/diabetes/statislics/meduse/fig1.him, 2013. |
Debiotech News Release, “Debiotech reveals its new miniaturized Disposable Insulin Nanopump™ for Diabetes therapy,” available at http://www.debiotech.com/news/nw 159.html Apr. 24, 2006, 3 pages. |
European Search Report and Opinion for European Application No. 17857364.8, dated Apr. 21, 2020, 8 pages. |
Grill et al., Exercise and Postprandial Lipid Metabolism: an Update on Potential Mechanisms and Interactions with High-Carbohydrate Diets/(Review), Elsevier 2003, pp. 122-132. (Year: 2003). |
Harvey et al., Quest for the Artificial Pancreas, IEEE 2010, pp. 53-62. (Year: 2010). |
Hurley, Dan. Artificial Pancreas Makers Race to Markel. Discover. Date published: Apr. 12, 2016. <http://discovermagazine.com/2016/may/13-priming-the-pump>. |
JDRF, Statistics: JDRF and Diabetes, http://jdrf.org/aboul-jdrf/facl-sheels/jdrf-anddiabeles- statistics/, 2014. |
Karnes, Chris. “Kids Mental Health App.” dribbble.com. Feb. 1, 2020. Accessed May 7, 2020. Available online at URL: https://dribbble.com/shots/9841070-Kids-Mental-Health-App (Year: 2020). |
Kumar, Rohit. “Health App.” dribbble.com. May 14, 2015. Accessed May 7, 2020. Available online at URL: https://dribbble.com/shots/2062723-Health-App (Year: 2015). |
Medtronic News Release, “Medtronic Receives FDA Approval for World's First Insulin Pump with Real-time Continuous Glucose Monitoring,” Apr. 13, 2006, 3 pages. |
Samuel Vozeh and Jean-Louis Steimer, Feedback Control Methods for Drug Dosage Optimisation, Concepts, Classification and Clinical Application, Clinical Pharmacokinetics, 10(6), pp. 457-476, Nov.-Dec. 1985. |
Shishir, Shahidl Islam. “Med-i App | Splash Home and Logo.” dribbble.com. Jul. 28, 2019. Accessed May 7, 2020. Available online at URL: https://dribbble.com/shots/6852974-Med-i-App-I-Splash-Home-and-Logo (Year: 2019). |
Simmons, Cory, “How to Make Your Own Button UI Kil with Super-Clean Syntax” Dec. 23, 2014, envato tuts+, site visited Sep. 19, 2019: https://webdesign.lutsplus.com/lutorials/how-lo-make-your--0wn-button-ui-kil-wilh-super-clean-syntax-cms-22946. |
Australian Examination Report from Australian Application No. 2017335762, dated Oct. 29, 2021, 3 pages. |
Dreyfuss, Henry. Symbol Sourcebook: An Authoritative Guide to International Graphic Symbols. Van Nostrand Reinhold, 1984. p. 52. (Year: 1984). |
U.S. Trademark Serial No. 85698749 to Mmillenniumm Group Ing. Filed Aug. 8, 2012. Retrieved Mar. 7, 2022 online via Trademark Electronic Search System (TESS). (Year: 2012). |
U.S. Trademark Serial No. 86854669 to DynoSense Corp. Filed Dec. 19, 2015. Retrieved Mar. 7, 2022 online via Trademark Electronic Search System (TESS). (Year: 2015). |
Chinese First Office Action for Chinese Application No. 201910969068.3 dated Nov. 21, 2022, 13 pages with translation. |
European Communication pursuant to Article 94(3) EPC for European Application No. 17857362.2, dated Mar. 20, 2023, 5 pages. |
“LifeScan Receives FDA Clearance for One Touch VerioSync Bluetooth Blood Glucose Meter” Mar. 7, 2013, posted at medgadget.com, [site visited May 30, 2023]. https://www.medgadget.com/2013/03/lifescan-receives-fda-clearance-for-onetouch-veriosync-bluetooth-blood-glucose-meter.html (Year: 2013). |
“SeebeckCell Technologies” Jul. 7, 2022, posted at greentownlabs.com, [site visited May 30, 2023]. https://web.archive.org/web/20220707134432/https://greentownlabs.com/members/seebeckcell-technologies (Year: 2022). |
Number | Date | Country | |
---|---|---|---|
20200001018 A1 | Jan 2020 | US |
Number | Date | Country | |
---|---|---|---|
62400366 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15717805 | Sep 2017 | US |
Child | 16566544 | US |